US20040126353A1 - Reducing hair growth, hair follicle and hair shaft size and hair pigmentation - Google Patents

Reducing hair growth, hair follicle and hair shaft size and hair pigmentation Download PDF

Info

Publication number
US20040126353A1
US20040126353A1 US10/434,309 US43430903A US2004126353A1 US 20040126353 A1 US20040126353 A1 US 20040126353A1 US 43430903 A US43430903 A US 43430903A US 2004126353 A1 US2004126353 A1 US 2004126353A1
Authority
US
United States
Prior art keywords
hair
composition
soymilk
isoflavones
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/434,309
Inventor
Miri Seiberg
Stanley Shapiro
Jue-Chen Liu
jonathan Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26843282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040126353(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/434,309 priority Critical patent/US20040126353A1/en
Publication of US20040126353A1 publication Critical patent/US20040126353A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/08Preparations for bleaching the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • A61Q7/02Preparations for inhibiting or slowing hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Definitions

  • This invention is related to methods and compositions effective for reducing hair growth. More specifically, the present invention is directed to methods for changing the rate of hair growth, reducing the size of the hair follicle and the hair shaft, and reducing hair shaft pigmentation, by topical application of either botanical extracts containing serine protease inhibitory activity and in particular soybean extracts such as soymilk, or mixtures and formulations of the above, combined with other active ingredients such as isoflavones.
  • Pseudofolliculitis barbae is an inflammatory hair disorder, most commonly found on the beard area. Inflammatory follicular papules result when hair tips penetrate into the skin rather than passing through the follicular orifice. This process is extremely common in black men because their hairs are frequently curly, exiting the skin at an acute angle. Close shaves, particularly with a razor blade, predispose them to pseudofolliculitis barbae. The most effective treatment available is to allow the hairs to grow well beyond the skin surface. Such a treatment is often not desired.
  • Hirsutism is a relatively frequent condition affecting about 4% of women. Facial hirsutism often interferes with personal and work activities, and temporary hair removal is a major component in the management of hirsute patients. Shaving is the most frequently used temporary method for facial hair, as plucking, waxing and depilatories are more difficult to tolerate and care must be taken to avoid folliculitis, pigmentation, and scarring. Cosmetic cover-ups are usually used to hide cuts and stubble and electrolysis and thermolysis may be used for permanent hair removal when affordable.
  • An alternative or complementary desired approach to hair removal would be a method to reduce hair growth, reduce hair follicle and hair shaft size and reduce hair shaft pigmentation. Such an approach could reduce the visibility of existing hair, making it softer and lighter. When combined with other methods of hair removal such a method could enhance and prolong the removal effect, and reduce the need and frequency of hair removal. Long term use of such an approach could lead to attenuated, soft, pigmentation-reduced hair growth, that is less visible and does not require the use of other removal methods.
  • Reduced hair growth is desired in the axilla area (fossa axillaris), where deodorants and anti-perspirants are used to control odor trapped within the axillary hairs. It would be desired to have products for under-arm use, which combine deodorant or anti-perspirant activities with reduced hair growth activity.
  • African type hair is unique in its morphology—a kinky hair shaft with variations in diameter. This complex shaft structure creates the need for specialized grooming products and procedures to ensure that the African type hair maintains cosmetic desired properties. It is desired to have products that reduce this complexity and make the African type hair more manageable, improving its appearance.
  • compositions and methods for affecting changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation by topically applying to the skin of a mammal an effective amount of a topically active composition comprising protease inhibitors, botanical extracts, and in particular legume extracts including, but not limited to, soymilk, for a period of time sufficient to affect hair growth, hair follicle and hair shaft size and hair shaft pigmentation.
  • a topically active compositions may be further combined with other active ingredients including, but not limited to, synthetic or naturally occurring isoflavones, to enhance the desired effects on hair growth and pigmentation.
  • compositions and methods of this invention provide a unique, convenient means for delaying hair growth, reducing hair follicle and hair shaft size and hair shaft pigmentation, by using serine protease inhibitors, botanical extracts of the legume family, and in particular, but not limited to, soymilk, containing serine protease inhibitory activity, and their combinations with isoflavones.
  • FIG. 1 A photograph of control and soymilk treated C57Bl/6 mouse hair (high magnification).
  • FIG. 2 Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day four of the hair cycle.
  • FIG. 3 Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day seven of the hair cycle, high and low magnifications.
  • FIG. 4 Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day 18 of the hair cycle.
  • FIG. 5 Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day 21 of the hair cycle.
  • FIG. 6 Histological sections of control, soymilk, and soymilk-derived proteins-treated C3H mouse hair follicles (High magnification) at day seven of the hair cycle.
  • FIG. 7 Histological sections of control, soymilk, and soymilk-derived proteins-treated C3H mouse hair follicles (lower magnifications) at day seven of the hair cycle.
  • FIG. 8 Histological sections of control and soymilk-treated C3H mouse hair follicles at day 21 of the hair cycle.
  • FIG. 9 A photograph of control and soymilk-derived proteins treated C3H mouse hair (high magnification).
  • FIG. 10 Histological sections of control and soymilk-derived proteins-treated C57Bl/6 mouse hair follicles (High magnification) at day eight of the hair cycle.
  • FIG. 11 A graph demonstrating the trypsin inhibitory activity of soymilk.
  • FIG. 12 Western blot of C57Bl/6 mouse skins throughout the hair cycle, demonstrating reduced tyrosinase and TRP-1 protein levels following soymilk treatment.
  • FIG. 13 Photographs of untreated and soymilk treated sides of human face, treated with soymilk daily for four weeks.
  • FIG. 14 Quantitative analysis of hair follicle dimensions with and without soymilk treatment.
  • FIG. 15 Photographs of human leg hair following five weeks of soymilk treatment on one leg.
  • FIG. 16 Photographs of control, soymilk, and isoflavone-enriched soymilk treated C57Bl/6 mouse hair (high magnification).
  • FIG. 17 Histological sections of control, soymilk, and isoflavone-enriched soymilk treated C57Bl/6 mouse skins at day 15 of the hair cycle, documenting the thickness and color of the hair shafts.
  • FIG. 18 Photograph of C57Bl/6 mouse hair after three weeks of treatment with various soymilk and isoflavones formulations.
  • mammal shall mean any member “of the higher vertebrate animals comprising the class Mammalia,” as defined in Webster's Medical Desk Dictionary 407 (1986), and includes but is not limited to humans.
  • (%, w/v) shall mean grams of a given component per 100 ml of the total composition.
  • Topically active agents suitable for use in the composition of the present invention include protease inhibitors and natural plant extracts having protease inhibitory activity and mixtures thereof.
  • Preferred protease inhibitors are serine protease inhibitors, and in particular Soybean Trypsin Inhibitor (“STI”) and the soybean-derived Bowman Birk Inhibitor (“BBI).
  • Preferred botanical extracts are of the legume family and in particular bean extracts, such as soymilk.
  • the protease inhibitors are present in an amount, based upon the total volume of the composition of the present invention, of from about 0.0001% (w/v) to about 20% (w/v), and more preferably from about 0.001% (w/v) to about 5% (w/v).
  • botanical aqueous extracts such as soymilk are present in an amount of 10-99% (v/v), and more preferably from 50-99% (v/v).
  • topically active agents such as described above, and in particular soymilk or soymilk containing formulations
  • isoflavones and in particular soybean-derived isoflavones
  • the inhibitory effect on hair growth, hair dimensions and hair pigmentation is enhanced.
  • the isoflavones are present in the botanical aqueous extracts such as soymilk in an amount of 0.000005-15% (v/v), and more preferably from 0.00001-10% (v/v).
  • the topically active composition of the present invention may be further comprised of a pharmaceutically or cosmetically acceptable vehicle capable of functioning as a delivery system to enable the penetration of the topically active agent into the hair follicle and the skin.
  • the pharmaceutical or cosmetic composition may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, depigmenting agents, anti-aging agents, hair removal agents, hair styling agents, sunscreens surfactants, foaming agents, conditioners, humectants, fragrances, colorants, viscosifiers, buffering agents, preservatives, and the like and mixtures thereof.
  • ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, depigmenting agents, anti-aging agents, hair removal agents, hair styling agents, sunscreens surfactants, foaming agents, conditioners, humectants, fragrances, colorants, viscosifiers, buffering agents, preservatives, and the like and mixtures thereof.
  • These will be combined in an amount which will not affect the serine protease inhibitory activity, in order to produce cosmetic or pharmaceutical products such as, non-exclusively, essences, creams, lotions, pastes, gels, powders, patches or injectables and the like for the
  • compositions of this invention may be applied prior to, concurrently with or after other active ingredients or compositions to enhance their effect.
  • the compositions of this invention may be applied in conjunction with one or more products whose purpose is to facilitate the removal of hair to to actually remove hair, reduce hair visibility, improve hair style or improve hair management.
  • the compositions of this invention may be applied topically prior to, during or following hair removal. They may be applied topically concurrently with one or more of the following group: depilatory agents, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair-removal products, after-shave products, deodorant, anti-perspirant, electrolysis, laser hair removal, light-induced hair removal, mask or bath additives.
  • compositions of this invention may be applied daily for at least four to eight weeks, by which an effect upon the appearance of hair should be observed. Application may be continued as long as desired to maintain the condition of the hair. Daily application to the face may mitigate the condition of pseudofolliculitis barbae and/or hirsutism; application to the axillary area may reduce hair growth under the arms and application to the scalp and hair may assist in managing and styling African-type hair.
  • the topically active pharmaceutical or cosmetic composition should be applied in an amount effective to effect changes in mammalian hair growth, hair follicle and hair shaft size and hair shaft pigmentation.
  • amount effective shall mean an amount sufficient to cover the region of skin surface where a delay in hair growth and hair pigmentation and reduced hair size are desired.
  • the composition is applied to the skin surface such that, based upon a square cm of skin surface, from about 2 ⁇ l/cm 2 to about 500 ⁇ l/cm 2 of topically active agent is present when a delay in hair growth, hair size and hair pigmentation is desired.
  • C57BI/6 or C3H mice male and female were obtained from Charles River (Kingston, N.Y.), at 8 -10 weeks of age and were in the resting (telogen) phase of their respective hair cycle. Hair growth was induced by wax depilation (plucking) of each respective animal's back fur according to the procedure set forth in Stenn, et al., “Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration,” 6 Skin Pharmacol. , 125-134 (1993) In C57Bl/6 and C3H mice, 8-10 weeks old, the growth phase (anagen) starts synchronously in all hair follicles at the time of depilation.
  • soymilk used in the formulations described below can be fresh soymilk as described above, or may be made from soybean powder and water.
  • the soybean powder is milled from soybeans and may also be lyophilized, spray dried, or freeze-dried and the resulting soymilk may or may not be filtered.
  • Such prepared soymilk may have from about 1 to about 90% by weight dry soybean powder.
  • soymilk powder made from lyophilized, spray dried or freeze-dried soymilk, with the addition of water and finished with or without filtration or homogenization.
  • Other methods of soybean extraction could also be used to create the active ingredients in the formulations described below.
  • the active ingredients could be extracted from ground soybeans using ethanol/water mixtures, followed by the removal of the ethanol from the extract, in such ways that the serine protease inhibitory activity of the soybean will be retained, and preferably that the protein STI will remain intact.
  • the soy products useful in this invention may be produced from all soybean species, regardless of their geographic origin, sun exposure, harvest time and the like. However, specific strains, geographic origins or growth conditions might be preferred. For example, but not limiting to, soybean strains particularly rich in its Soybean Trypsin Inhibitor (STI) content or in isoflavone content, or growth conditions that result in STI or isoflavone enrichment in the bean, might be preferred. It should be noted that the soy products useful in the compositions of this invention have a distinctive odor, which may be tolerable in some cultures, but is undesired in others.
  • STI Soybean Trypsin Inhibitor
  • the odor of the compositions of this invention may be reduced by using soybean products derived from specific strains of soybeans known to produce reduced-odor, including, but not limited to, lipoxygenase-2-deficient beans and those having modified sugar profile, and the like.
  • a process to reduce oxygen levels in the formulation may also reduce the odor.
  • Various masking agents or fragrances may also be used to mask the odor.
  • compositions of this invention may further comprise surfactants, moisturizers, humectants, conditioners, fragrances, colorants, preservatives, anti-oxidants, depigmenting agents, hair removal agents, anti-aging agents, sunscreens, foaming agents, cosmetic adjuvants, buffering agents or mixtures thereof.
  • compositions of this invention may be left on the skin for a period sufficient to effect changes.
  • the compositions of this invention may be applied to the skin daily treatment for at least about four weeks, more preferably, the composition should applied daily for at least eight weeks.
  • Another method according to this invention is a method to reduce or prevent pseudofolliculitis barbae.
  • Daily application of the compositions of this invention may reduce or prevent this condition.
  • the compositions of this invention may also be applied daily to the axilliary area to reduce hair growth.
  • the compositions of this invention may be applied daily to the scalp to style and improve management of African type hair.
  • soymilk-based formulations could be used to reduce pigmentation. All these formulations could also be used to reduce hair growth.
  • soymilk formulations and soymilk formulations containing isoflavones are shown in table 2 below.
  • An example for an isoflavones preparation that could be used in this invention is Flavosterone SE from Ichimaru, Japan, which contains about 0.1% pure isoflavones. In all these formulations, soymilk could be replaced with the appropriate quantities of soybean powder or soymilk powder and water.
  • Soymilk Essence formulations Soybean Essences 1 6 8 21 22 23 24 25 26 Soymilk 87.42% 89.04% 96.09% 96.05% 96.05% 95.70% 94.40% 94.40% 92.40% Phenoxyethanol 0.73% Phenoxyethanol and 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% Parabens Glycerin 2.50% 2.50% Cyclomethicone 2.00% Aluminum Starch 0.75% Ocetyl Succinate Sucrose Cocoate 1.00% 1.00% PEG-6 3.00% 3.00% Capric/Caprylic Triglycerides Disodium EDTA 0.10% 0.10% 0.05% 0.05% 0.05% 0.05% 0.05% Polyacrylamide/Laur 2.50% 2.75% 2.90% 2.90% 2.90% 3.20% 3.50% 3.50% 3.50% 3.50% eth-7/C 13-14 Isoparrafin Ascorbic Acid 0.01% 1.00% Butylated 0.10% 0.01% 0.05%
  • Soybean trypsin inhibitor (STI) and Bowman-Birk inhibitor (BBI), from Sigma-Aldrich Corporation were mixed into a 0.1M phosphate buffered saline (PBS, Gibco-BRL, Gaithersburg, Md.), pH 7.4, in concentrations of 1% to 0.001% (w/v).
  • PBS 0.1M phosphate buffered saline
  • BBI Bowman-Birk inhibitor
  • Non-ionic liposomes preparations such as those disclosed in Niemiec et al., “Influence of Nonionic Liposomal Composition On Topical Delivery of Peptide Drugs Into Pilosebaceous Units: An In Vivo Study Using the Hamster Ear Model,” 12 Pharm. Res. 1184-88 (1995) (“Niemiec”), which is incorporated by reference herein in its entirety, are well known in the art, and are described our U.S. patent application (Attorney Docket No. JBP 430).
  • GDL liposomes were prepared as set forth in Niemiec, et al., above, with the exception of the following changes: the non-ionic liposomal formulation contained glycerol dilaurate (Emulsynt GDL, ISP Van Dyk)/cholesterol (Croda)/polyoxyethylene-10-stearyl ether (Brij76, ICI)/polyoxyethylene-9-lauryl ether, as at ratio of 37.5:12.5:33.3:16.7. Either PBS or Hepes buffer, 0.05M, pH 7.4 (Gibco-BRL of Gaithersburg, Md.) were used as the aqueous phase in the preparation of the liposomes.
  • FIG. 1 is a picture of the mice fur, showing the difference in hair appearance, color, size and thickness following soymilk treatment.
  • FIG. 3 shows two sets of histological sections stained with F&M, of lower and higher magnification. These sections are from day seven of the hair cycle.
  • the upper panel shows that soymilk treated skin has smaller, shorter, and less pigmented hair follicles than the untreated control.
  • the lower panel shows a higher magnification of the follicles, further demonstrating the difference in hair follicle and hair shaft size and pigmentation following soymilk treatment.
  • FIG. 4 shows low magnification of F&M stained skin sections at day 18 of the hair cycle. At this magnification it is obvious that soymilk treatment results in reduced hair follicle size, which leads to reduced hair shaft length and thickness, and reduced total pigment deposition within the treated follicles.
  • FIG. 5 shows skin sections at day 21 of the hair cycle, with two magnifications.
  • the upper panel demonstrates that the control animals were in the catagen stage, when hair follicles are regressing. Soymilk treated follicles, on the other hand, had already completed the catagen stage, as they are shown in telogen, the resting stage. This indicates that not only the hair cycle was delayed following soymilk treatment, it was also prematurely terminated.
  • the lower panel demonstrates the catagen control follicle and the shorter, telogen (resting) soymilk-treated follicle using higher magnification.
  • FIG. 8 shows F&M stained skin sections at day 21 is of the hair cycle. As shown for the C57Bl/6 mice, following soymilk treatment the hair cycle terminates prematurely. Soymilk treated follicles are in the resting state, while untreated control follicles are still in catagen.
  • Example 4 The experiments described in Example 4 were repeated using STI, BBI, and soymilk.
  • STI and BBI were used in a PBS-liposome vehicle as described in Example 3.
  • Visual observations throughout the hair cycle confirmed that both STI and BBI could delay hair growth and reduce hair follicle and hair shaft size, similar to soymilk (see hair pictures in FIG. 9).
  • Using high concentrations of STI or BBI the effect on hair growth and pigmentation was substantial.
  • FIG. 6 shows lower magnification sections of the same day into the hair cycle, demonstrating smaller hair follicles and hair shafts and reduced pigmentation, relative to untreated control, with soymilk, STI or BBI treatment.
  • FIG. 10 shows that STI and BBI have the same effect in C57Bl/6 mice too, demonstrating smaller and less pigmented follicles.
  • STI and BBI are soybean-derived serine protease inhibitors, found in soymilk, that could delay hair growth, reduce hair follicle and hair shaft size and reduce hair pigmentation.
  • STI and BBI could represent a part of the soymilk ingredients that affects hair growth.
  • soymilk In order to support the hypothesis that STI and BBI in soymilk are involved in the hair growth effects described above, we tested soymilk for its serine protease inhibitory activity.
  • An enzymatic assay was performed using “Enzchek”, a protease digestion fluorescent test system made by Molecular Probes of Eugene, Oreg. Using 100 units of trypsin (from Sigma chemicals, St. Louis Mo.) the test system produced fluorescence reading of about 1100 units. This reaction was inhibited with increasing concentrations of STI, as expected from a known trypsin inhibitor. Serial dilutions of soymilk were tested in this assay, and found to inhibit trypsin activity. As shown in FIG. 11, soymilk exerts trypsin inhibitory activity similar to about 0.2% of pure STI. This suggests that soymilk could exert its hair growth effect, at least in part, by STI and BBI.
  • Tyrosinase and TRP-1 proteins are dramatically affected by soymilk treatment. Tyrosinase and TRP-1 levels are reduced, and the duration of the expression is shortened. These two factors affect overall hair pigmentation, which is reduced due to the reduced level and shorter duration of melanogenesis.
  • FIG. 14 shows a computerized image analysis of the facial hair length, thickness and total area, following four weeks of soymilk treatment. All images were analyzed with Image Pro Plus 3.0 software (Media Cybernetics, Silver Spring, Md.). Data are presented as average of 180 hair shafts of each side of the face, with standard deviation (SigmaPlot® 5.0, SPSS Science, Chicago, Ill.). Statistical analysis was performed using SigmaStat® 2.0 (SPSS Science) software, demonstrating a statistical significant difference in all measured parameters, following soymilk treatment.
  • One leg was treated daily, for four weeks, with soymilk.
  • Visual observations indicate slower hair growth on the treated site. Hair shafts were reduced in number and were shorter and thinner than those of the untreated site, as shown in FIG. 15. These observations further confirm the effect of soymilk on hair growth. Examples 8 and 9 together confirm that the effect of soymilk on human hair growth is not related to the method of hair removal or to the body part being treated.
  • Soymilk Formulations Enriched With Isoflavones are Preferred to Soymilk Formulations in Reducing Hair Growth and Pigmentation.
  • mice treated with Soymilk essence 23 show reduced hair growth and nicer hair appearance. This effect was more pronounced with the use of soymilk Essence 30, demonstrating that isoflavone-enriched soymilk formulations are superior to soymilk formulations in reducing hair-growth.
  • FIG. 17 shows histological skin sections of the treated mice, at day 15 of the treatment. The hair shafts documented in these sections clearly demonstrate the reduction in hair shaft dimensions, the reduced level of pigmentation within the hair shaft, and the increased smoothness of the hair shaft following the Soymilk Essence treatments.
  • Soymilk Formulations Enriched With Isoflavones are Preferred to Isoflavone Formulations Which are Effective in Reducing Hair Growth and Pigmentation.
  • Example 4 The experiments described in Example 4 were repeated, using formulations described in Table 2 above, of soymilk essence with or without increasing concentrations of isoflavones. These Soy Essence formulations were compare to similar formulations, where the soymilk component only was replaced with water. These three sets of formulations (Soy Essence, isoflavones, Soy Essence containing additional isoflavones) were prepared to test the possibility that isoflavones might be sufficient for the effect observed on hair growth.
  • FIG. 18 shows the C57Bl/6 mouse hair following three weeks of topical treatment, as described in example 4. Both untreated control mice and placebo treated mice have long and less “ordered” hair.
  • Soymilk Essence 23 reduces hair growth and leads to a nicer appearance, as described earlier in this application.
  • Soymilk Essence formulations containing 1, 5 and 10% of a 0.1% isoflavones containing extract result in a superior effect on hair growth.
  • formulations containing isoflavones but no soymilk demonstrate milder, and not as superior effect as when combined with soymilk.
  • soymilk formulations containing isoflavone could reduce hair growth.
  • soymilk formulations containing isoflavones reduce hair growth to a higher degree than formulations containing isoflavones alone.
  • test lotions and placebo were used on the respective legs for the duration of the study with no other lotions used on the lower legs. Panelists were instructed to apply the test lotions twice daily, morning and evenings and were also instructed to try to refrain from shaving their lower legs until after each weekly evaluation. On evaluation days, the investigator visually inspected the panelists' legs for any clinical signs of irritation and compared legs for hair growth attenuation. Self-assessment questionnaires were completed by panelists at each evaluation time point (Weeks 1, 2, 3 and 4). In addition, Hi-scope images (2.5 cm in diameter for each image, KH-2400R, Hirox) were obtained at each time point using a MX-MACROZ lens (Hirox).
  • Results from panelists' self-assessment questionnaires showed that panelists felt that the test lotions attenuated hair growth and softened the feel of leg hair, compared to the placebo lotion. Panelists felt that the hair felt less coarse and less stubbley. The majority of the panelists believed that the test lotions were attenuating leg hair growth or altering the texture of the hair so that it felt smoother and less coarse. Hi Scope analysis further demonstrated that the hair re-growth following treatment with Soymilk Essence 23 or 30 seemed to be growing in the same direction and was more uniform in shape, texture and appearance. In contrast, the hair that re-grew on the placebo-treated legs grew in different directions, differing in length, angle of growth and thickness.
  • This Example clearly demonstrate the effect of soymilk formulations in delaying and reducing hair growth, and enabling the growth of softer, less coarse and more managed and directionally-organized hair.

Abstract

The present invention utilizes natural and/or synthetic serine protease inhibitory agents or botanical extracts containing serine protease inhibitory activity, with or without the addition of one or more isoflavones and/or additional natural extracts containing one or more isoflavones, and their ability to affect changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation.

Description

    FIELD OF THE INVENTION
  • This invention is related to methods and compositions effective for reducing hair growth. More specifically, the present invention is directed to methods for changing the rate of hair growth, reducing the size of the hair follicle and the hair shaft, and reducing hair shaft pigmentation, by topical application of either botanical extracts containing serine protease inhibitory activity and in particular soybean extracts such as soymilk, or mixtures and formulations of the above, combined with other active ingredients such as isoflavones. [0001]
  • BACKGROUND OF THE INVENTION
  • One main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed essentially for social and cosmetic purposes. [0002]
  • Many procedures are used to remove unwanted hair including shaving, electrolysis, plucking, laser and light therapies and injection of therapeutic antiandrogens. These conventional methods are not without their shortcomings. Shaving, for instance, may result in nicks and cuts in the skin's surface, may leave a perception of an increase in the rate of hair regrowth, and may also leave undesirable stubble. While electrolysis may keep an area free of unwanted hair for a prolonged period of time, the process is often expensive and painful and may further result in scarring. Not only may plucking cause pain and discomfort, but it often result in a poor removal of short hair. Several unwanted side effects, such as effects on muscularity, often accompany the use of antiandrogens. For these reasons, better methods for reducing hair growth are needed. [0003]
  • Pseudofolliculitis barbae is an inflammatory hair disorder, most commonly found on the beard area. Inflammatory follicular papules result when hair tips penetrate into the skin rather than passing through the follicular orifice. This process is extremely common in black men because their hairs are frequently curly, exiting the skin at an acute angle. Close shaves, particularly with a razor blade, predispose them to pseudofolliculitis barbae. The most effective treatment available is to allow the hairs to grow well beyond the skin surface. Such a treatment is often not desired. [0004]
  • Hirsutism is a relatively frequent condition affecting about 4% of women. Facial hirsutism often interferes with personal and work activities, and temporary hair removal is a major component in the management of hirsute patients. Shaving is the most frequently used temporary method for facial hair, as plucking, waxing and depilatories are more difficult to tolerate and care must be taken to avoid folliculitis, pigmentation, and scarring. Cosmetic cover-ups are usually used to hide cuts and stubble and electrolysis and thermolysis may be used for permanent hair removal when affordable. [0005]
  • An alternative or complementary desired approach to hair removal, would be a method to reduce hair growth, reduce hair follicle and hair shaft size and reduce hair shaft pigmentation. Such an approach could reduce the visibility of existing hair, making it softer and lighter. When combined with other methods of hair removal such a method could enhance and prolong the removal effect, and reduce the need and frequency of hair removal. Long term use of such an approach could lead to attenuated, soft, pigmentation-reduced hair growth, that is less visible and does not require the use of other removal methods. [0006]
  • Reduced hair growth is desired in the axilla area (fossa axillaris), where deodorants and anti-perspirants are used to control odor trapped within the axillary hairs. It would be desired to have products for under-arm use, which combine deodorant or anti-perspirant activities with reduced hair growth activity. [0007]
  • African type hair is unique in its morphology—a kinky hair shaft with variations in diameter. This complex shaft structure creates the need for specialized grooming products and procedures to ensure that the African type hair maintains cosmetic desired properties. It is desired to have products that reduce this complexity and make the African type hair more manageable, improving its appearance. [0008]
  • It would be desirable to provide a method for chemically or naturally affecting hair growth, hair follicle and hair shaft size and hair shaft pigmentation, which does not cause unwanted side effects to the user. [0009]
  • SUMMARY OF THE INVENTION
  • In accordance with the present invention, we have found compositions and methods for affecting changes in mammalian hair growth, hair follicle and hair shaft size and hair pigmentation by topically applying to the skin of a mammal an effective amount of a topically active composition comprising protease inhibitors, botanical extracts, and in particular legume extracts including, but not limited to, soymilk, for a period of time sufficient to affect hair growth, hair follicle and hair shaft size and hair shaft pigmentation. Such topically active compositions may be further combined with other active ingredients including, but not limited to, synthetic or naturally occurring isoflavones, to enhance the desired effects on hair growth and pigmentation. [0010]
  • The compositions and methods of this invention provide a unique, convenient means for delaying hair growth, reducing hair follicle and hair shaft size and hair shaft pigmentation, by using serine protease inhibitors, botanical extracts of the legume family, and in particular, but not limited to, soymilk, containing serine protease inhibitory activity, and their combinations with isoflavones.[0011]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee. [0012]
  • The invention will be more fully understood and further advantages will become apparent when reference is made to the following detailed description of the invention and the accompanying drawings in which: [0013]
  • FIG. 1: A photograph of control and soymilk treated C57Bl/6 mouse hair (high magnification). [0014]
  • FIG. 2: Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day four of the hair cycle. [0015]
  • FIG. 3: Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at day seven of the hair cycle, high and low magnifications. [0016]
  • FIG. 4: Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at [0017] day 18 of the hair cycle.
  • FIG. 5: Histological sections of control and soymilk-treated C57Bl/6 mouse hair follicles at [0018] day 21 of the hair cycle.
  • FIG. 6: Histological sections of control, soymilk, and soymilk-derived proteins-treated C3H mouse hair follicles (High magnification) at day seven of the hair cycle. [0019]
  • FIG. 7: Histological sections of control, soymilk, and soymilk-derived proteins-treated C3H mouse hair follicles (lower magnifications) at day seven of the hair cycle. [0020]
  • FIG. 8: Histological sections of control and soymilk-treated C3H mouse hair follicles at [0021] day 21 of the hair cycle.
  • FIG. 9: A photograph of control and soymilk-derived proteins treated C3H mouse hair (high magnification). [0022]
  • FIG. 10: Histological sections of control and soymilk-derived proteins-treated C57Bl/6 mouse hair follicles (High magnification) at day eight of the hair cycle. [0023]
  • FIG. 11: A graph demonstrating the trypsin inhibitory activity of soymilk. [0024]
  • FIG. 12: Western blot of C57Bl/6 mouse skins throughout the hair cycle, demonstrating reduced tyrosinase and TRP-1 protein levels following soymilk treatment. [0025]
  • FIG. 13: Photographs of untreated and soymilk treated sides of human face, treated with soymilk daily for four weeks. [0026]
  • FIG. 14: Quantitative analysis of hair follicle dimensions with and without soymilk treatment. [0027]
  • FIG. 15: Photographs of human leg hair following five weeks of soymilk treatment on one leg. [0028]
  • FIG. 16: Photographs of control, soymilk, and isoflavone-enriched soymilk treated C57Bl/6 mouse hair (high magnification). [0029]
  • FIG. 17: Histological sections of control, soymilk, and isoflavone-enriched soymilk treated C57Bl/6 mouse skins at [0030] day 15 of the hair cycle, documenting the thickness and color of the hair shafts.
  • FIG. 18: Photograph of C57Bl/6 mouse hair after three weeks of treatment with various soymilk and isoflavones formulations.[0031]
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
  • As used herein, “mammal” shall mean any member “of the higher vertebrate animals comprising the class Mammalia,” as defined in Webster's Medical Desk Dictionary 407 (1986), and includes but is not limited to humans. As used herein “(%, w/v)” shall mean grams of a given component per 100 ml of the total composition. [0032]
  • Topically active agents suitable for use in the composition of the present invention include protease inhibitors and natural plant extracts having protease inhibitory activity and mixtures thereof. Preferred protease inhibitors are serine protease inhibitors, and in particular Soybean Trypsin Inhibitor (“STI”) and the soybean-derived Bowman Birk Inhibitor (“BBI). Preferred botanical extracts are of the legume family and in particular bean extracts, such as soymilk. Preferably, the protease inhibitors are present in an amount, based upon the total volume of the composition of the present invention, of from about 0.0001% (w/v) to about 20% (w/v), and more preferably from about 0.001% (w/v) to about 5% (w/v). Preferably, botanical aqueous extracts such as soymilk are present in an amount of 10-99% (v/v), and more preferably from 50-99% (v/v). [0033]
  • We have unexpectedly found that when topically active agents such as described above, and in particular soymilk or soymilk containing formulations, are enriched with isoflavones, and in particular soybean-derived isoflavones, the inhibitory effect on hair growth, hair dimensions and hair pigmentation is enhanced. Preferably, the isoflavones are present in the botanical aqueous extracts such as soymilk in an amount of 0.000005-15% (v/v), and more preferably from 0.00001-10% (v/v). [0034]
  • If the delivery parameters of the topically active pharmaceutical or cosmetic agent so require, the topically active composition of the present invention may be further comprised of a pharmaceutically or cosmetically acceptable vehicle capable of functioning as a delivery system to enable the penetration of the topically active agent into the hair follicle and the skin. [0035]
  • The pharmaceutical or cosmetic composition may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, depigmenting agents, anti-aging agents, hair removal agents, hair styling agents, sunscreens surfactants, foaming agents, conditioners, humectants, fragrances, colorants, viscosifiers, buffering agents, preservatives, and the like and mixtures thereof. These will be combined in an amount which will not affect the serine protease inhibitory activity, in order to produce cosmetic or pharmaceutical products such as, non-exclusively, essences, creams, lotions, pastes, gels, powders, patches or injectables and the like for the reduction of hair growth, hair size and hair pigmentation. [0036]
  • The compositions of this invention may be applied prior to, concurrently with or after other active ingredients or compositions to enhance their effect. For example, the compositions of this invention may be applied in conjunction with one or more products whose purpose is to facilitate the removal of hair to to actually remove hair, reduce hair visibility, improve hair style or improve hair management. The compositions of this invention may be applied topically prior to, during or following hair removal. They may be applied topically concurrently with one or more of the following group: depilatory agents, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair-removal products, after-shave products, deodorant, anti-perspirant, electrolysis, laser hair removal, light-induced hair removal, mask or bath additives. [0037]
  • The compositions of this invention may be applied daily for at least four to eight weeks, by which an effect upon the appearance of hair should be observed. Application may be continued as long as desired to maintain the condition of the hair. Daily application to the face may mitigate the condition of pseudofolliculitis barbae and/or hirsutism; application to the axillary area may reduce hair growth under the arms and application to the scalp and hair may assist in managing and styling African-type hair. [0038]
  • The topically active pharmaceutical or cosmetic composition should be applied in an amount effective to effect changes in mammalian hair growth, hair follicle and hair shaft size and hair shaft pigmentation. As used herein “amount effective” shall mean an amount sufficient to cover the region of skin surface where a delay in hair growth and hair pigmentation and reduced hair size are desired. Preferably, the composition is applied to the skin surface such that, based upon a square cm of skin surface, from about 2 μl/cm[0039] 2 to about 500 μl/cm2 of topically active agent is present when a delay in hair growth, hair size and hair pigmentation is desired.
  • We have unexpectedly found that when topically active agents, such as soymilk, or isoflavone-enriched soymilk are topically applied to an animal's skin, a significant delay in hair growth, hair follicle and hair shaft size and hair shaft pigmentation was achieved. We further believe that since the hair growth cycle for humans is often slower than that for mice, it is further likely that the hair growth delay in humans would be considerably longer than in mice. [0040]
  • The invention illustratively disclosed herein suitably might be practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein. Several examples are set forth below to further illustrate the nature of the invention and the manner of carrying it out. However, the invention should not be considered as being limited to the details thereof. [0041]
  • EXAMPLES Example 1
  • Depilation of Test Subjects in the Mouse System [0042]
  • C57BI/6 or C3H mice (male and female) were obtained from Charles River (Kingston, N.Y.), at 8 -10 weeks of age and were in the resting (telogen) phase of their respective hair cycle. Hair growth was induced by wax depilation (plucking) of each respective animal's back fur according to the procedure set forth in Stenn, et al., “Glucocorticoid Effect on Hair Growth Initiation: A Reconsideration,” 6 Skin Pharmacol. , 125-134 (1993) In C57Bl/6 and C3H mice, 8-10 weeks old, the growth phase (anagen) starts synchronously in all hair follicles at the time of depilation. As illustrated in Table 1, the following observations were noticed at the induction site: [0043]
    TABLE 1
    Observations at Induction Site
    Morphological and Histological
    Days Post-Induction Observations at the induction site
     1-2 (early anagen) new follicle starts to grow
     3 to 4 hair follicles were fully developed,
    but the hair shafts were not yet
    visible
     7 to 8 (late anagen) each mouse had very dark skin; their
    hair shafts are histologically
    visible
    11-12 the hair shafts started to penetrate
    through the epidermis.
    14 each mouse was covered with short
    hairs
    19 the regression of the follicle
    (catagen) was observed histologically
    21 to 25 the hair follicle is back to resting
    phase.
  • As shown in Table 1, the hair growth was visible several days after depilation as the pink skin of the animal began to darken. This is likely due to hair pigmentation in the shaft since the C57BI/6 and C3H mice contained melanocytes only in the hair follicles and not in the dorsal epidermis. Similar hair growth pattern was documented in our international application No. PCT/US 97/11033, when chemical depilation using commercially available products was performed. [0044]
  • Since the murine hair cycle varies not only between strains, but also amongst individual animals, the status of the hair cycle was analyzed in each animal on study. A 2 cm by 1 cm skin sample was isolated from each mouse with scissors, fixed with a 10% buffered formalin solution having a pH of about 6.9-7.1 at 25° C. (Stephens Scientific), and then formed into a paraffin block according to well-known procedures. The block was then microtomed, and sections were stained with H&E or Fontana-Mason stain. Sections were examined histologically in order to verify the phase of the hair cycle, the size of the hair follicle and hair shaft and the level of hair pigmentation, using procedures well known in the art. Hair length was assessed visually, and by using a low magnification (×8) dissecting microscope. [0045]
  • This Example, as well as the one described in our international application No. PCT/US 97/11033, shows that the hair growth cycle for C57BI/6 and C3H mice averaged about 25 days and reports similar timing of hair follicle and shaft development regardless of the method used for depilation. [0046]
  • Example 2
  • Preparation of Soymilk and Soymilk Formulations [0047]
  • One way to make soymilk is to soak the soybeans in deionized or purified water for several hours, and grind them after they were fully hydrated, with the addition of small quantities of water. (The grinding process allows the soybean milk to be extracted). After collection, the soybean milk may be filtered to remove any residual parts of the bean husk. The soymilk used in the formulations described below can be fresh soymilk as described above, or may be made from soybean powder and water. The soybean powder is milled from soybeans and may also be lyophilized, spray dried, or freeze-dried and the resulting soymilk may or may not be filtered. Such prepared soymilk may have from about 1 to about 90% by weight dry soybean powder. Another example is the use of soymilk powder, made from lyophilized, spray dried or freeze-dried soymilk, with the addition of water and finished with or without filtration or homogenization. Other methods of soybean extraction could also be used to create the active ingredients in the formulations described below. For example, the active ingredients could be extracted from ground soybeans using ethanol/water mixtures, followed by the removal of the ethanol from the extract, in such ways that the serine protease inhibitory activity of the soybean will be retained, and preferably that the protein STI will remain intact. [0048]
  • The soy products useful in this invention may be produced from all soybean species, regardless of their geographic origin, sun exposure, harvest time and the like. However, specific strains, geographic origins or growth conditions might be preferred. For example, but not limiting to, soybean strains particularly rich in its Soybean Trypsin Inhibitor (STI) content or in isoflavone content, or growth conditions that result in STI or isoflavone enrichment in the bean, might be preferred. It should be noted that the soy products useful in the compositions of this invention have a distinctive odor, which may be tolerable in some cultures, but is undesired in others. If necessary, the odor of the compositions of this invention may be reduced by using soybean products derived from specific strains of soybeans known to produce reduced-odor, including, but not limited to, lipoxygenase-2-deficient beans and those having modified sugar profile, and the like. A process to reduce oxygen levels in the formulation may also reduce the odor. Various masking agents or fragrances may also be used to mask the odor. [0049]
  • The compositions of this invention may further comprise surfactants, moisturizers, humectants, conditioners, fragrances, colorants, preservatives, anti-oxidants, depigmenting agents, hair removal agents, anti-aging agents, sunscreens, foaming agents, cosmetic adjuvants, buffering agents or mixtures thereof. [0050]
  • The compositions of this invention may be left on the skin for a period sufficient to effect changes. For example, the compositions of this invention may be applied to the skin daily treatment for at least about four weeks, more preferably, the composition should applied daily for at least eight weeks. [0051]
  • Another method according to this invention is a method to reduce or prevent pseudofolliculitis barbae. Daily application of the compositions of this invention may reduce or prevent this condition. The compositions of this invention may also be applied daily to the axilliary area to reduce hair growth. Furthermore, the compositions of this invention may be applied daily to the scalp to style and improve management of African type hair. [0052]
  • As shown in our co-pending U.S. patent application (Attorney Docket No. JBP 430), numerous soymilk-based formulations could be used to reduce pigmentation. All these formulations could also be used to reduce hair growth. Some particularly preferred examples of soymilk formulations and soymilk formulations containing isoflavones are shown in table 2 below. An example for an isoflavones preparation that could be used in this invention is Flavosterone SE from Ichimaru, Japan, which contains about 0.1% pure isoflavones. In all these formulations, soymilk could be replaced with the appropriate quantities of soybean powder or soymilk powder and water. [0053]
    TABLE 2
    Soymilk Essence formulations:
    Soybean Essences 1 6 8 21 22 23 24 25 26
    Soymilk  87.42%  89.04% 96.09%  96.05%  96.05%  95.70%  94.40%  94.40%  92.40% 
    Phenoxyethanol  0.73%
    Phenoxyethanol and  1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00%
    Parabens
    Glycerin  2.50%  2.50%
    Cyclomethicone  2.00%
    Aluminum Starch  0.75%
    Ocetyl Succinate
    Sucrose Cocoate  1.00%  1.00%
    PEG-6  3.00%  3.00%
    Capric/Caprylic
    Triglycerides
    Disodium EDTA  0.10%  0.10% 0.05% 0.05% 0.05% 0.05%
    Polyacrylamide/Laur  2.50%  2.75% 2.90% 2.90% 2.90% 3.20% 3.50% 3.50% 3.50%
    eth-7/C13-14
    Isoparrafin
    Ascorbic Acid  0.01% 1.00%
    Butylated  0.10% 0.01% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05%
    Hydroxytoluene
    Polysorbate 20  0.50%
    Lactoferrin 1.00% 1.00% 1.00%
    Tocopherol 1.00%
    TOTAL 100.00% 100.00%  100%  100%  100%  100%  100%  100%  100%
    27 28 29 30 31 32 33 34 35
    Soymilk 90.70%  94.70%  85.70%  90.70%  93.70%  94.70% 
    Phenoxyethanol and 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00%
    Parabens
    Glycerin 5.00%
    Disodium EDTA 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05%
    Polyacrylamide/Laur 3.20% 3.20% 3.20% 3.20% 3.20% 3.20% 3.20% 3.20% 3.20%
    eth-7/C13-14
    Isoparrafin
    Ascorbic Acid
    Butylated 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05% 0.05%
    Hydroxytoluene
    Deionized Water 90.70%  90.70%  85.70% 
    Dow Corning 200 1.00%
    Fluid
    Flavosterone SE 10.00% 5.00% 2.00% 1.00%
    Soymilk Powder 5.00%
    Soybean Extract 5% 10%
    using Ethanol/Water
    Mixture
    TOTAL  100%  100%  100%  100%  100%  100%  100%  100%  100%
  • Example 3
  • Preparation of Topically Active Compositions Containing Soybean Derived Protease Inhibitors [0054]
  • Soybean trypsin inhibitor (STI) and Bowman-Birk inhibitor (BBI), from Sigma-Aldrich Corporation were mixed into a 0.1M phosphate buffered saline (PBS, Gibco-BRL, Gaithersburg, Md.), pH 7.4, in concentrations of 1% to 0.001% (w/v). Four volumes of the resulting solutions were then mixed with 1 volume of (100 mg/ml) liposomes vehicle, which was prepared by the methods described in Niemiec et. al, in order to yield the topically active composition. Non-ionic liposomes preparations, such as those disclosed in Niemiec et al., “Influence of Nonionic Liposomal Composition On Topical Delivery of Peptide Drugs Into Pilosebaceous Units: An In Vivo Study Using the Hamster Ear Model,” 12 Pharm. Res. 1184-88 (1995) (“Niemiec”), which is incorporated by reference herein in its entirety, are well known in the art, and are described our U.S. patent application (Attorney Docket No. JBP 430). GDL liposomes were prepared as set forth in Niemiec, et al., above, with the exception of the following changes: the non-ionic liposomal formulation contained glycerol dilaurate (Emulsynt GDL, ISP Van Dyk)/cholesterol (Croda)/polyoxyethylene-10-stearyl ether (Brij76, ICI)/polyoxyethylene-9-lauryl ether, as at ratio of 37.5:12.5:33.3:16.7. Either PBS or Hepes buffer, 0.05M, pH 7.4 (Gibco-BRL of Gaithersburg, Md.) were used as the aqueous phase in the preparation of the liposomes. [0055]
  • Example 4
  • Soymilk Delays Hair Growth and Reduce Hair Follicle and Hair Shaft Size and Hair Shaft Pigmentation [0056]
  • C57Bl/6 mice were induced for a new hair cycle as described in Example 1, and treated daily with soymilk. Animals were observed daily for their hair growth pattern, and skin biopsies were taken at important time points of the hair cycle. As a result of soymilk treatment the hair growth of the treated mice was delayed, and their hairs were visibly thinner, and smoother to touch. Treated mice did not show skin darkness at days 7-8 of the hair cycle, as expected, and hair shafts were not visible at days 11-12 as in the control animals. In average, the hair cycle of the soymilk treated mice was delayed by 3-6 days. FIG. 1 is a picture of the mice fur, showing the difference in hair appearance, color, size and thickness following soymilk treatment. [0057]
  • Histological examination of the biopsied skin samples confirmed these observations. As shown in FIG. 2 by Fontana-Mason (F&M) staining, at day four of the hair cycle the untreated hair follicle is fully developed, as expected, containing all the cellular layers and pigment deposition. In contrast, the soymilk treated sample, (shown at same magnification), shows a smaller and not as fully developed hair follicle, with no pigment deposition. [0058]
  • FIG. 3 shows two sets of histological sections stained with F&M, of lower and higher magnification. These sections are from day seven of the hair cycle. The upper panel shows that soymilk treated skin has smaller, shorter, and less pigmented hair follicles than the untreated control. The lower panel shows a higher magnification of the follicles, further demonstrating the difference in hair follicle and hair shaft size and pigmentation following soymilk treatment. [0059]
  • FIG. 4 shows low magnification of F&M stained skin sections at [0060] day 18 of the hair cycle. At this magnification it is obvious that soymilk treatment results in reduced hair follicle size, which leads to reduced hair shaft length and thickness, and reduced total pigment deposition within the treated follicles.
  • FIG. 5 shows skin sections at [0061] day 21 of the hair cycle, with two magnifications. The upper panel demonstrates that the control animals were in the catagen stage, when hair follicles are regressing. Soymilk treated follicles, on the other hand, had already completed the catagen stage, as they are shown in telogen, the resting stage. This indicates that not only the hair cycle was delayed following soymilk treatment, it was also prematurely terminated. The lower panel demonstrates the catagen control follicle and the shorter, telogen (resting) soymilk-treated follicle using higher magnification.
  • Example 5
  • The Effects of Soymilk on Hair Growth, Size and Pigmentation are Reproducible in C3H Mice [0062]
  • In order to verify that the effect of soymilk on hair growth is not specific to C57Bl/6 mice, we repeated the experiment described in Example 4 using the brown haired (Agouti) C3H mice. The results of these experiments were similar both visually and histologically. Soymilk delayed hair growth and reduced hair follicle and hair shaft size and pigment deposition in the C3H mice. [0063]
  • Histological analysis confirmed these visual observations. As shown in the upper panel of FIG. 6, using F&M staining, at day seven of the hair cycle soymilk treated follicles are smaller and accumulate less pigment than untreated controls. The upper panel of FIG. 7 (F&M staining) shows a lower magnification of the same skin sections, demonstrating the thinner and less pigmented follicles following soymilk treatment. [0064]
  • FIG. 8 shows F&M stained skin sections at [0065] day 21 is of the hair cycle. As shown for the C57Bl/6 mice, following soymilk treatment the hair cycle terminates prematurely. Soymilk treated follicles are in the resting state, while untreated control follicles are still in catagen.
  • Example 6
  • The Effects of Soymilk and Soybean Derived Serine Protease Inhibitors on Hair Growth, Size and Pigmentation [0066]
  • In search for a mechanism to explain the effect of soymilk on hair growth, we tested the effect of the soymilk-derived serine protease inhibitors, STI and BBI. We had shown earlier that these proteins induce depigmentation in skin, by affecting the PAR-2 pathway (U.S. patent application, Attorney Docket No. JBP 430). [0067]
  • The experiments described in Example 4 were repeated using STI, BBI, and soymilk. STI and BBI were used in a PBS-liposome vehicle as described in Example 3. Visual observations throughout the hair cycle confirmed that both STI and BBI could delay hair growth and reduce hair follicle and hair shaft size, similar to soymilk (see hair pictures in FIG. 9). Using high concentrations of STI or BBI, the effect on hair growth and pigmentation was substantial. [0068]
  • Histological analysis confirmed these finding. As shown in FIG. 6, at day seven of the [0069] hair cycle 1% of STI and 1% of BBI reduce hair follicle and hair shaft size and hair shaft pigmentation in C3H mice. FIG. 7 shows lower magnification sections of the same day into the hair cycle, demonstrating smaller hair follicles and hair shafts and reduced pigmentation, relative to untreated control, with soymilk, STI or BBI treatment. FIG. 10 shows that STI and BBI have the same effect in C57Bl/6 mice too, demonstrating smaller and less pigmented follicles. Taken together, this example shows that STI and BBI are soybean-derived serine protease inhibitors, found in soymilk, that could delay hair growth, reduce hair follicle and hair shaft size and reduce hair pigmentation. STI and BBI could represent a part of the soymilk ingredients that affects hair growth.
  • In order to support the hypothesis that STI and BBI in soymilk are involved in the hair growth effects described above, we tested soymilk for its serine protease inhibitory activity. An enzymatic assay was performed using “Enzchek”, a protease digestion fluorescent test system made by Molecular Probes of Eugene, Oreg. Using 100 units of trypsin (from Sigma chemicals, St. Louis Mo.) the test system produced fluorescence reading of about 1100 units. This reaction was inhibited with increasing concentrations of STI, as expected from a known trypsin inhibitor. Serial dilutions of soymilk were tested in this assay, and found to inhibit trypsin activity. As shown in FIG. 11, soymilk exerts trypsin inhibitory activity similar to about 0.2% of pure STI. This suggests that soymilk could exert its hair growth effect, at least in part, by STI and BBI. [0070]
  • Example 7
  • Soymilk Induces Changes in Tyrosinase and TRP-1 Protein Expression [0071]
  • The histological analyses of soymilk treated skin samples described in the examples above show dramatic reduction in pigment deposition within the hair follicle. To further understand the mechanism of soymilk-induced depigmentation, we studied tyrosinase, the key enzyme in melanogenesis and Tyrosinase-Related Protein-1 (TRP-1), the enzyme that stabilizes tyrosinase. C57Bl/6 and C3H mice were treated as described above, and samples were collected throughout the study for protein analysis. Protein extraction and Western blot analysis were performed using standard procedures, such as the one described in Current Protocols in Cell Biology, Edited by Juan S. Bonifacino et al. Chapter 6: Electrophoresis and Immunoblotting. Copyright 1999 by John Wiley & Sons, Inc., which is incorporated herein by reference in its entirety. An example of one such study is shown in FIG. 12. [0072]
  • Equal amounts of skin-extracted proteins were probed with the anti-tyrosinase antibody “anti PEP1”, and with the anti-TRP-1 antibody “anti PEP7” which are described in Jimenez, M., Kameyama, K., Maloy, W L, Tomita Y., and Hearing, V. Mammalian tyrosinase: biosynthesis, processing and modulation by melanocyte stimulating hormone. Proc. Natl. Acad. Sci. USA (1988), 85:3830-34, and Jimenez, M., K., Maloy, W L, and Hearing, V. Specific identification of an authentic tyrosinase clone. J. Biol. Chem. (1989) 264:3397-3403, which are incorporated herein by reference in their entirety. [0073]
  • As shown in FIG. 12, The expression of Tyrosinase and TRP-1 proteins is dramatically affected by soymilk treatment. Tyrosinase and TRP-1 levels are reduced, and the duration of the expression is shortened. These two factors affect overall hair pigmentation, which is reduced due to the reduced level and shorter duration of melanogenesis. [0074]
  • Example 8
  • Soymilk Reduces Human Facial Hair Length and Thickness [0075]
  • An individual male with dark facial hair who shaves daily was treating the right side of his face with soymilk, immediately after shaving, for five weeks. By the third week, and more noticeably by the forth week, the hair of the treated side was visually lighter and felt smoother to touch. Digital pictures at different magnifications were taken throughout the treatment period, using Hi-Scope. These pictures clearly demonstrate the reduced size and thickness of the hair shafts at the treated side. An example of such pictures is shown in FIG. 13, demonstrating the difference in hair shaft thickness and density at four weeks of treatment. Since both sides of the face were shaved at the same time, and pictures of both sides were taken at the same time, the difference in length of the facial hair indicates slower growth rate at the treated area. [0076]
  • FIG. 14 shows a computerized image analysis of the facial hair length, thickness and total area, following four weeks of soymilk treatment. All images were analyzed with Image Pro Plus 3.0 software (Media Cybernetics, Silver Spring, Md.). Data are presented as average of 180 hair shafts of each side of the face, with standard deviation (SigmaPlot® 5.0, SPSS Science, Chicago, Ill.). Statistical analysis was performed using SigmaStat® 2.0 (SPSS Science) software, demonstrating a statistical significant difference in all measured parameters, following soymilk treatment. [0077]
  • Example 9
  • Soymilk Reduces Human Legs Hair length and Thickness [0078]
  • Hair was wax-depilated of two symmetrical areas of the medial part of the legs, below the knee, in one individual. One leg was treated daily, for four weeks, with soymilk. Visual observations indicate slower hair growth on the treated site. Hair shafts were reduced in number and were shorter and thinner than those of the untreated site, as shown in FIG. 15. These observations further confirm the effect of soymilk on hair growth. Examples 8 and 9 together confirm that the effect of soymilk on human hair growth is not related to the method of hair removal or to the body part being treated. [0079]
  • Example 10
  • Soymilk Formulations Enriched With Isoflavones are Preferred to Soymilk Formulations in Reducing Hair Growth and Pigmentation. [0080]
  • The experiments described in Example 4 were repeated, using two formulations described in Table 2 above, Soymilk Essence 23 which is a soymilk-based formulation, and [0081] soymilk Essence 30 which is identical to Soymilk Essence 23 except the addition of 5% of a 0.1% isoflavones extract. As shown in FIG. 16, mice treated with Soymilk essence 23 show reduced hair growth and nicer hair appearance. This effect was more pronounced with the use of soymilk Essence 30, demonstrating that isoflavone-enriched soymilk formulations are superior to soymilk formulations in reducing hair-growth. FIG. 17 shows histological skin sections of the treated mice, at day 15 of the treatment. The hair shafts documented in these sections clearly demonstrate the reduction in hair shaft dimensions, the reduced level of pigmentation within the hair shaft, and the increased smoothness of the hair shaft following the Soymilk Essence treatments.
  • Example 11
  • Soymilk Formulations Enriched With Isoflavones are Preferred to Isoflavone Formulations Which are Effective in Reducing Hair Growth and Pigmentation. [0082]
  • The experiments described in Example 4 were repeated, using formulations described in Table 2 above, of soymilk essence with or without increasing concentrations of isoflavones. These Soy Essence formulations were compare to similar formulations, where the soymilk component only was replaced with water. These three sets of formulations (Soy Essence, isoflavones, Soy Essence containing additional isoflavones) were prepared to test the possibility that isoflavones might be sufficient for the effect observed on hair growth. FIG. 18 shows the C57Bl/6 mouse hair following three weeks of topical treatment, as described in example 4. Both untreated control mice and placebo treated mice have long and less “ordered” hair. Soymilk Essence 23 reduces hair growth and leads to a nicer appearance, as described earlier in this application. Soymilk Essence formulations containing 1, 5 and 10% of a 0.1% isoflavones containing extract result in a superior effect on hair growth. However, formulations containing isoflavones but no soymilk demonstrate milder, and not as superior effect as when combined with soymilk. This example demonstrates that soymilk formulations containing isoflavone could reduce hair growth. This example further demonstrates that soymilk formulations containing isoflavones reduce hair growth to a higher degree than formulations containing isoflavones alone. [0083]
  • Example 12
  • Soy Essence Formulations Affect Human Hair Growth [0084]
  • The efficacy and irritancy potential of [0085] Soymilk Essence 23 and 30 compared to a placebo formulation were examined in a blinded placebo-controlled four-week test with twelve pre-menopausal female panelists ages 29 to 45 by evaluations by the study investigator, self-assessment by panelists and Hi-scope image analysis. Panelists signed an Informed Consent and were instructed about study procedures and expectations and were asked to shave that night. At the baseline visit the following day, two test lotions were distributed to each panelist (Day 1), a placebo lotion and either soymilk Essence 23 or 30. The lotions were randomly assigned to either the right leg or left leg. The test lotions and placebo were used on the respective legs for the duration of the study with no other lotions used on the lower legs. Panelists were instructed to apply the test lotions twice daily, morning and evenings and were also instructed to try to refrain from shaving their lower legs until after each weekly evaluation. On evaluation days, the investigator visually inspected the panelists' legs for any clinical signs of irritation and compared legs for hair growth attenuation. Self-assessment questionnaires were completed by panelists at each evaluation time point ( Weeks 1, 2, 3 and 4). In addition, Hi-scope images (2.5 cm in diameter for each image, KH-2400R, Hirox) were obtained at each time point using a MX-MACROZ lens (Hirox).
  • No panelists dropped from the study for any product-related reason. No signs of irritation were seen in any of the study panelists at any time point, nor was any irritation reported when self-assessed by panelists at any time point during the study. [0086]
  • For the purpose of hair counts all hair, including “stubble”, were counted in the given 2.5 cm field for each panelist at each time point. Results showed a decrease in lower leg hair counts by [0087] week 5 for Soymilk Essence 30 and by week 4 for Soymilk Essence 23. The placebo treated legs did not show a change in mean leg hair counts throughout the study although the standard deviations were large. The growth rate was calculated by dividing the length of time (in days) since the panelist last shaved, by the average length of leg hairs for that panelist, which was calculated from the hi-scope images using Image Pro Plus analysis for each panelist at each test site. The results are documented in Table 3, demonstrating that both Soymilk Essences 23 and 30 treatments resulted in reduced hair growth rate compared to placebo.
    TABLE 3
    Mean leg hair growth rates following Soymilk Essence or
    placebo treatment
    Soymilk Soymilk
    Week Location Essence 30 Essence 23 Placebo
    0 Upper 0.211 (±0.07) 0.184 (±0.07) 0.243 (±0.07)
    (baseline) Lower 0.248 (±0.08) 0.191 (±0.06) 0.235 (±0.09)
    1 Upper 0.216 (±0.05) 0.153 (±0.03) 0.211 (±0.06)
    Lower 0.178 (±0.08) 0.213 (±0.03) 0.188 (±0.07)
    2 Upper 0.232 (±0.11) 0.181 (±0.04) 0.221 (±0.07)
    Lower 0.236 (±0.12) 0.195 (±0.07) 0.217 (±0.09)
    3 Upper 0.241 (±0.06) 0.185 (±0.09) 0.285 (±0.13)
    Lower 0.213 (±0.10) 0.147 (±0.04) 0.253 (±0.12)
    4 Upper 0.234 (±0.07) 0.209 (±0.11) 0.211 (±0.09)
    Lower 0.194 (±0.05) 0.208 (±0.07) 0.220 (±0.04)
  • Results from panelists' self-assessment questionnaires showed that panelists felt that the test lotions attenuated hair growth and softened the feel of leg hair, compared to the placebo lotion. Panelists felt that the hair felt less coarse and less stubbley. The majority of the panelists believed that the test lotions were attenuating leg hair growth or altering the texture of the hair so that it felt smoother and less coarse. Hi Scope analysis further demonstrated that the hair re-growth following treatment with [0088] Soymilk Essence 23 or 30 seemed to be growing in the same direction and was more uniform in shape, texture and appearance. In contrast, the hair that re-grew on the placebo-treated legs grew in different directions, differing in length, angle of growth and thickness.
  • This Example clearly demonstrate the effect of soymilk formulations in delaying and reducing hair growth, and enabling the growth of softer, less coarse and more managed and directionally-organized hair. [0089]

Claims (52)

We claim:
1. A method for effecting changes in mammalian hair appearance, hair growth, hair pigmentation and hair follicle and hair shaft size, comprising topical application to the skin of a mammal an effective amount of a topically active composition comprising one or more compounds derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.
2. The method of claim 1 wherein said extract contains at least one serine protease inhibitory activity.
3. The method of claim 2 wherein said at least one serine protease inhibitory active agent is a serine protease inhibitor.
4. The method of claim 3 wherein said at least one serine protease inhibitor is present in an amount, based upon the total volume of the topically active composition, of from about 0.0001% (w/v) to 20% (w/v).
5. The method of claim 4 wherein the at least one serine protease inhibitor is present in an amount, based upon the total volume of the topically active composition, of from about 0.001% (w/v) to about 5% (w/v).
6. The method of claim 1 wherein one of said changes is a delay in hair growth, reduced hair follicle and hair shaft size and reduced hair pigmentation.
7. The method of claim 1 wherein said topically active composition further comprises a pharmaceutically or cosmetically acceptable vehicle.
8. The method of claim 1 wherein said topically active composition further comprises one or more isoflavones.
9. The method of claim 8 wherein said topically active composition further comprises a pharmaceutically or cosmetically acceptable vehicle.
10. The method of claim 1 wherein said topically active composition further comprises natural extracts containing one or more isoflavones.
11. The method of claim 1 wherein said composition is applied topically in conjunction with one or more products whose purpose is to either facilitate the removal of hair or actually remove hair or reduce hair visibility or improve hair style or improve hair management.
12. The method of claim 1 wherein said composition is applied topically before or following hair removal.
13. The method of claim 1 wherein said composition is applied topically during hair removal.
14. The method of claim 1 wherein said composition is applied topically in conjunction with one or more of the group consisting of: depilatory agents, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair-removal products, after-shave products, deodorant, anti-perspirant, electrolysis, laser hair removal, light-induced hair removal, mask, bath additives.
15. The method of claim 1 further comprising leaving said composition on said skin for a period sufficient to effect said changes.
16. The method of claim 1 wherein said period is daily treatment for at least about four weeks.
17. A method according to claim 16 wherein said composition is applied daily for at least eight weeks.
18. A method according to claim 1 wherein said composition is applied daily to reduce or prevent pseudofolliculitis barbae.
19. A method according to claim 1 wherein said composition is applied daily to the axilliary area to reduce hair growth.
20. A method according to claim 1 wherein said composition is applied daily to the scalp to style and improve management of African type hair.
21. A method according to claim 1 wherein said composition is added daily to a bath.
22. A method according to claim 1 wherein said composition is used daily on facial or body parts for delaying hair growth and reducing hair visibility in sufferers of hirsutism.
23. A composition for affecting changes in mammalian hair growth, hair pigmentation and hair shaft and follicle size, comprising topically applying to skin of a mammal an effective amount of a topically active composition comprising one or more compounds derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.
24. The composition of claim 23 wherein the extract contains at least one serine protease inhibitory activity.
25. The composition of claim 24 wherein the at least one serine protease inhibitory active agent is present in an amount, based upon the total volume of the topically active composition, of from about 0.0001% (w/v) to about 20% (w/v).
26. The composition of claim 25 wherein the at least one protease inhibitory active agent is present in an amount, based upon the total volume of the topically active composition, of from about 0.001% (w/v) to about 5% (w/v).
27. The composition of claim 23 wherein the composition further comprises one or more isoflavones.
28. The composition of claim 23 wherein the composition further comprises one or more natural extracts containing one or more isoflavones.
29. The composition of claim 23 wherein the composition further comprises surfactants, moisturizers, humectants, foaming agents, cosmetic adjuvants, buffering agents, preservatives, anti-oxidants, conditioners, depigmenting agents, hair removal agents, anti-aging agents, sunscreens, fragrances, colorants, or mixtures thereof.
30. The composition of claim 23 wherein said composition is in the form of liquid, cream, gel, paste, powder, essence, mousse, emulsion, film patch or spray.
31. The composition of claim 23 wherein said composition further comprises one or more products whose purpose is to either facilitate the removal of hair or actually remove hair or reduce hair visibility or improve hair management.
32. The composition of claim 23 wherein said composition further comprises one or more of the group consisting of: depilatory cream, shampoo, hair conditioner, styling gel, hair care products, waxing products, shaving products, hair removal products, after-shave products, deodorant, anti-perspirant, pre- or post -electrolysis products, pre- or post-laser hair removal products, pre- or post-light-induced hair removal products, mask, bath additives.
33. A composition according to claim 23 wherein said compound is derived from legumes.
34. A composition according to claim 33 wherein said compound is derived from soy, lima and/or black beans.
35. A composition according to claim 34 wherein said compound is selected from the group consisting of soybean milk, limabean milk, blackbean milk, soybean extract, limabean extract, blackbean extract, soybean paste, limabean paste, blackbean paste, soybean powder, blackbean powder, limabean powder, soymilk powder, blackbean milk powder and limabean milk powder and mixtures thereof.
36. A composition according to claim 35 wherein said compound is a fraction of soybean milk, soybean extract, soybean paste, limabean milk, limabean extract, limabean paste, blackbean milk, blackbean extract, blackbean paste, soybean powder, blackbean powder, limabean powder, soymilk powder, blackbean milk powder and limabean milk powder and mixtures thereof.
37. A composition according to claim 35 comprising bean milk in an amount of from about 1 to about 99% by weight.
38. A composition according to claim 35 comprising soybean powder, soymilk powder or a mixture thereof in an amount of from about 1 to about 99% by weight.
39. A composition according to claim 36 comprising soybean trypsin inhibitor, limabean trypsin inhibitor or blackbean trypsin inhibitor in an amount of from about 0.0001 to about 20% by weight.
40. A composition according to claim 33 said composition further comprising one or more isoflavones.
41. A composition according to claim 33 said composition further comprising one or more natural extracts containing one or more isoflavones.
42. A composition according to claim 40 wherein said one or more isoflavones are present in said composition in amount of from about 0.00001 to about 0.1% by weight.
43. A composition according to claim 41 wherein said one or more natural extract containing said one or more isoflavones are present in said composition in amount of from about 0.00001 to about 0.1% by weight.
44. A cosmetic composition according to claim 23, said composition further comprising a cosmetically-acceptable vehicle.
45. A composition according to claim 23 wherein said composition further comprises liposomes.
46. A composition according to claim 45 wherein said composition comprises glycerol dilaurate, cholesterol, polyoxyethylene-10-stearyl ether and polyoxyethylene-9-lauryl ether.
47. A composition according to claim 23 wherein said composition comprises from about 1 to about 99% bean milk, from about 0.1 to about 20% emulsifier and preservatives in an effective amount.
48. A composition according to claim 23 wherein said composition comprises from about 0.5 to about 20% soybean powder or soymilk powder, from about 0.1 to about 20% emulsifier and preservatives in an effective amount.
49. A composition according to claim 47 wherein said composition further comprises one or more isoflavones in an amount of from about 0.00001 to about 0.1%.
50. A composition according to claim 47 wherein said composition further comprises one or more natural extracts comprising one or more isoflavones in an amount of from about 0.0001 to about 0.1%.
51. A composition according to claim 23 wherein said composition further comprises one or more isoflavones in an amount of from about 0.0001 to about 0.1%.
52. A composition according to claim 48 wherein said composition further comprises one or more natural extracts comprising one or more isoflavones in an amount of from about 0.0005 to about 0.05%.
US10/434,309 1999-07-27 2003-12-01 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation Abandoned US20040126353A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/434,309 US20040126353A1 (en) 1999-07-27 2003-12-01 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14577499P 1999-07-27 1999-07-27
US09/621,565 US7985404B1 (en) 1999-07-27 2000-07-21 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US10/434,309 US20040126353A1 (en) 1999-07-27 2003-12-01 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/621,565 Division US7985404B1 (en) 1999-07-27 2000-07-21 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation

Publications (1)

Publication Number Publication Date
US20040126353A1 true US20040126353A1 (en) 2004-07-01

Family

ID=26843282

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/621,565 Expired - Fee Related US7985404B1 (en) 1999-07-27 2000-07-21 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US10/253,736 Abandoned US20030064048A1 (en) 1999-07-27 2002-09-23 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US10/434,309 Abandoned US20040126353A1 (en) 1999-07-27 2003-12-01 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/621,565 Expired - Fee Related US7985404B1 (en) 1999-07-27 2000-07-21 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US10/253,736 Abandoned US20030064048A1 (en) 1999-07-27 2002-09-23 Reducing hair growth, hair follicle and hair shaft size and hair pigmentation

Country Status (10)

Country Link
US (3) US7985404B1 (en)
EP (1) EP1074240B1 (en)
JP (1) JP2001072555A (en)
KR (1) KR20010015444A (en)
CN (1) CN100337685C (en)
AT (1) ATE474551T1 (en)
CA (1) CA2314562C (en)
DE (1) DE60044697D1 (en)
ES (1) ES2347316T3 (en)
HK (1) HK1032540A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092497A1 (en) * 2006-12-22 2010-04-15 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
US20050004561A1 (en) * 2003-07-01 2005-01-06 Lynn Halas Method for removing hair
DE60309027T2 (en) * 2003-08-26 2007-05-10 Johnson & Johnson Consumer France Sas Stabilized antiperspirant agent containing soy products
KR20060125746A (en) * 2003-10-29 2006-12-06 죤슨 앤 죤슨 컨슈머 프랑스 에스에이에스 Compositions comprising soy products and dioic acids
WO2005067953A1 (en) 2004-01-16 2005-07-28 Cognis France S.A.S. Uses for the extract of a plant of the family asclepiadaceae
DE102004017971A1 (en) * 2004-04-12 2005-10-27 Leica Microsystems (Schweiz) Ag Stand, especially for surgical microscopes, with a force storage element
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
US20070203240A1 (en) * 2006-02-27 2007-08-30 The Procter & Gamble Company Personal care compositions and methods for regulating mammalian hair growth
US20080008818A1 (en) * 2006-06-23 2008-01-10 Miri Seiberg Partially denatured whole soybean extracts and methods of use thereof
US20080089960A1 (en) * 2006-10-16 2008-04-17 Miri Seiberg Use of Legume Products for the Treatment and Prevention of Radiotherapy-Induced Skin Damage
US20100016782A1 (en) * 2008-07-16 2010-01-21 John Erich Oblong Method of Regulating Hair Growth
GB201110132D0 (en) * 2011-06-16 2011-07-27 Reckitt & Colman Overseas compositions
ITRM20120576A1 (en) * 2012-11-19 2014-05-20 Cinzia Marchese EFFECTIVE COMPOSITION IN THE SLOWDOWN OF PILIFERAL GROWTH
ITUB20153691A1 (en) * 2015-09-17 2017-03-17 Bmg Pharma Srl TOPIC ANTI-IRSUTISM COMPOSITION
IT201700027628A1 (en) * 2017-03-13 2018-09-13 Neilos S R L COMPOSITION FOR USE IN REDUCING PELI GROWTH
US11718829B2 (en) 2017-07-28 2023-08-08 Breakthrough Tech Llc Methods and compositions for manufacturing extracellular matrix

Citations (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2876164A (en) * 1957-08-01 1959-03-03 Dome Chemicals Inc Dermatological preparation containing defatted soy bean flour
US4007266A (en) * 1968-05-03 1977-02-08 Choay S.A. Pharmaceutical composition containing vitamin B12, process of making the same and method of treatment
US4151304A (en) * 1976-11-05 1979-04-24 Lever Brothers Company Method and composition for moisturizing the skin
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
US4254105A (en) * 1975-10-11 1981-03-03 The Lion Dentifrice Co., Ltd. Multiple emulsion having a form of water/oil/water phase and process for preparation thereof, and multiple emulsion type cosmetics
US4331692A (en) * 1971-07-23 1982-05-25 Ulla Drevici Cocoa fruits and products
US4368187A (en) * 1981-08-03 1983-01-11 Eli Lilly And Company Sensitive-skin care regime
US4370315A (en) * 1977-02-22 1983-01-25 Sederma Post-depilatory composition reducing progressively the growth of body hair
US4382960A (en) * 1981-08-03 1983-05-10 Eli Lilly And Company Cosmetic cleanser formulation
US4427670A (en) * 1980-03-27 1984-01-24 Mitsubishi Chemical Industries Limited Skin preparation
US4434095A (en) * 1979-02-04 1984-02-28 Institute Organicheskogo Sinteza Cyclic analogue of naturally-occurring phagocytosis-stimulant peptide - threonyl-cyclo-[-N.sup.ε -lysyl-prolyl-arginyl]
US4437895A (en) * 1981-07-23 1984-03-20 Societe Anonyme Dite: L'oreal Mixture of vegetable oils based on jojoba oil and cosmetic compositions comprising the mixture
US4439418A (en) * 1981-07-29 1984-03-27 Henkel Kgaa Topical preparations for the treatment of seborrhea and process for inhibiting sebum production
US4512973A (en) * 1983-10-12 1985-04-23 Genentech, Inc. Method for overcoming trypsin inhibition
US4515778A (en) * 1981-03-12 1985-05-07 Wolfgang Kastell Preparation for conditioning and grooming the hair
US4578267A (en) * 1981-09-15 1986-03-25 Morton Thiokol, Inc. Skin conditioning polymer containing alkoxylated nitrogen salts of sulfonic acid
US4584190A (en) * 1983-11-17 1986-04-22 Kao Corporation Novel chalcone derivatives and ultraviolet absorbers comprising the same
US4727088A (en) * 1984-02-06 1988-02-23 Neutrogena Corporation Retinoid composition having enhanced bioavailability and percutaneous absorption
US4824662A (en) * 1987-06-15 1989-04-25 Vi-Jon Laboratories, Inc. Nail polish remover
US4834076A (en) * 1985-04-17 1989-05-30 Millet Jean M Device for treating the external human epithelium, process for its manufacture and process for using such a device
US4895839A (en) * 1987-07-10 1990-01-23 INDENZA S.p.A. Pharmaceutical and cosmetic compositions containing complexes of flavanolignans with phospholipids
US4906457A (en) * 1988-09-06 1990-03-06 Washington State University Research Foundation, Inc. Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer
US5002761A (en) * 1988-05-02 1991-03-26 Henkel Kommanditgesellschaft Auf Aktien Hair treatment compositions containing natural ingredients
US5104655A (en) * 1987-07-27 1992-04-14 Indena S.P.A. Polyunsaturated acids having vasokinetic action and pharmaceutical and cosmetic formulations containing them
US5110603A (en) * 1991-01-31 1992-05-05 Kao Corporation Bathing preparation for colloidal material
US5116605A (en) * 1989-03-09 1992-05-26 Alt John P Composition and skin treatment method therewith for mitigating acne and male-pattern baldness
US5179091A (en) * 1990-06-22 1993-01-12 Adir Et Compagnie Chalcones
US5188823A (en) * 1991-02-07 1993-02-23 Stepan Company Antiperspirant formulations
US5192332A (en) * 1983-10-14 1993-03-09 L'oreal Cosmetic temporary coloring compositions containing protein derivatives
US5194252A (en) * 1989-07-27 1993-03-16 Vijon Laboratories, Inc. Moisture retaining aftershave
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
US5306444A (en) * 1990-08-24 1994-04-26 Shiseido Company Ltd. Washing composition capable of preventing and ameliorating skin irritation
US5310734A (en) * 1991-07-05 1994-05-10 Rhone-Poulenc Rorer Phospholipid composition
US5393519A (en) * 1992-03-27 1995-02-28 Helene Curtis, Inc. Shampoo compositions
US5397497A (en) * 1992-08-07 1995-03-14 Solvay Fluor Und Derivate Gmbh Bath additive composition containing polyglycerol fatty acid ester mixture
US5407675A (en) * 1990-08-10 1995-04-18 Etemad-Moghadam; Parviz Method and composition for use on the scalp and eyebrow region of a subject
US5411742A (en) * 1992-08-24 1995-05-02 L'oreal Compositions for the treatment of acne containing a derivative of salicylic acid and derivatives of salicylic acid
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5503832A (en) * 1994-02-15 1996-04-02 De Stoutz; Jean-Christian Method for extracting the soluble material from oil-bearing beans or seeds
US5505946A (en) * 1994-04-01 1996-04-09 Trustees Of Univ Of Pa Bowman-birk inhibitor concentrate compositions and methods for the treatment of pre-malignant tissue
US5510391A (en) * 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
US5595984A (en) * 1991-11-25 1997-01-21 Richardson-Vicks Inc. Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
US5601833A (en) * 1993-12-30 1997-02-11 L'oreal Protective, nutritive and/or firming composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
US5603949A (en) * 1991-08-01 1997-02-18 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives, for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
US5605894A (en) * 1991-11-25 1997-02-25 Richardson-Vicks Inc. Compositions for regulating skin wrinkles and/or skin atrophy
US5607692A (en) * 1993-12-30 1997-03-04 L'oreal Depigmenting composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
US5607666A (en) * 1993-12-22 1997-03-04 L'oreal Cosmetic or dermatological powder, its preparation process and its uses
US5614215A (en) * 1993-12-30 1997-03-25 L'oreal Cosmetic composition for the simultaneous treatment of the surface and deep layers of the skin, its use
US5614180A (en) * 1993-08-30 1997-03-25 Helene Curtis, Inc. Shampoo-conditioner composition
US5618522A (en) * 1995-01-20 1997-04-08 The Procter & Gamble Company Emulsion compositions
US5620692A (en) * 1993-12-23 1997-04-15 Nurture, Inc. Oat oil compositions with useful cosmetic and dermatological properties
US5622690A (en) * 1990-04-05 1997-04-22 Nurture, Inc. Seed-derived proteinaceous compositions for reduction of sunburn cell formation
US5626868A (en) * 1992-02-18 1997-05-06 L'oreal Cosmetic and/or pharmaceutical composition containing a dispersion of lipid vesicles, process for the preparation of the said dispersion and dispersion of lipid vesicles
US5629015A (en) * 1993-12-30 1997-05-13 L'oreal Composition for combating ageing acting simultaneously on the surface layers and deep layers of the skin and use thereof
US5712356A (en) * 1993-11-26 1998-01-27 Ciba Vision Corporation Cross-linkable copolymers and hydrogels
US5720772A (en) * 1992-10-20 1998-02-24 Esc Medical Systems Ltd. Method and apparatus for therapeutic electromagnetic treatment
US5723148A (en) * 1995-01-05 1998-03-03 Novartis Corp. Topical pharmaceutical compositions
US5741496A (en) * 1993-09-21 1998-04-21 Laboratoires De Biologie Vegetale Yves Rocher Process for the treatment of skins having dry areas and greasy areas
US5863546A (en) * 1997-03-02 1999-01-26 Swinehart; James M Cosmetic composition
US5869031A (en) * 1995-03-23 1999-02-09 Pierre Fabre Dermo-Cosmetique Depigmenting dermatological and/or cosmetic composition
US5871743A (en) * 1996-10-31 1999-02-16 Chajuss; Daniel Topical application of soy molasses
US5871823A (en) * 1996-06-19 1999-02-16 Huels Aktiengesellschaft Hydrophilic coating of surfaces of polymeric substrates
US5871480A (en) * 1991-10-29 1999-02-16 Thermolase Corporation Hair removal using photosensitizer and laser
US5880314A (en) * 1995-11-24 1999-03-09 Mitsui Chemicals, Inc. Hydrochalcone derivatives, cosmetic compositions containing said derivatives and methods of producing the same
US5885593A (en) * 1995-09-28 1999-03-23 The Andrew Jergens Company Skin care composition including cyclodextrin materials and method for treating skin therewith
US5885600A (en) * 1997-04-01 1999-03-23 Burlington Bio-Medical & Scientific Corp. Natural insect repellent formula and method of making same
US5885948A (en) * 1995-02-15 1999-03-23 The Procter & Gamble Company Crystalline hydroxy waxes as oil in water stabilizers for skin cleansing liquid composition
US5885596A (en) * 1997-07-23 1999-03-23 Bristol-Myers Squibb Company Methods and compositions for fine lines and/or wrinkles
US5885617A (en) * 1994-07-12 1999-03-23 Bpsi Holdings, Inc. Moisture barrier film coating composition, method, and coated form
US6013250A (en) * 1995-06-28 2000-01-11 L'oreal S. A. Composition for treating hair against chemical and photo damage
US6013255A (en) * 1994-04-18 2000-01-11 Gist-Brocades B.V. Stable water-in-oil emulsions
US6018001A (en) * 1997-01-23 2000-01-25 Menicon Co., Ltd. Process for producing contact lens with hydrophilic surface and contact lens obtained thereby
US6017893A (en) * 1997-08-29 2000-01-25 Natures Sunshine Products, Inc. Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
US6017549A (en) * 1997-09-30 2000-01-25 E-L Management Corp. Non-irritating cosmetic and pharmaceutical compositions
US6019962A (en) * 1995-11-07 2000-02-01 The Procter & Gamble Co. Compositions and methods for improving cosmetic products
US6030931A (en) * 1998-02-03 2000-02-29 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Foaming cleansing skin product
US6033680A (en) * 1994-12-06 2000-03-07 The Procter & Gamble Company Shelf stable skin cleansing liquid with gel forming polymer and lipid
US6045548A (en) * 1996-11-07 2000-04-04 Cynosure, Inc. Alexandrite laser system for hair removal and method therefor
US6045779A (en) * 1994-02-18 2000-04-04 Henkel Kommanditgesellschaft Auf Aktien Skin and hair aerosol foam preparations containing an alkyl polyglycoside and vegetable oil
US6048520A (en) * 1992-09-24 2000-04-11 Helene Curtis, Inc. Clear leave-on hair treatment composition and method
US6051602A (en) * 1998-03-16 2000-04-18 The Procter & Gamble Company Methods for regulating skin appearance
US6054137A (en) * 1997-12-19 2000-04-25 Societe L'oreal S.A. Promoting epidermal renewal with phloroglucinol
US6173762B1 (en) * 1993-07-07 2001-01-16 Kabushiki Kaisha Kobe Seiko Sho Heat exchanger tube for falling film evaporator
US6180662B1 (en) * 1994-12-13 2001-01-30 Beiersdorf Ag Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
US6183761B1 (en) * 1998-03-16 2001-02-06 The Procter & Gamble Company Compositions for regulating skin appearance
US6217572B1 (en) * 1998-05-22 2001-04-17 Edward L. Tobinick Apparatus and method employing lasers for removal of hair
US6358242B1 (en) * 1999-11-12 2002-03-19 Ceramoptec Industries, Inc. Post laser treatment for permanent hair removal
US20020034489A1 (en) * 1999-06-10 2002-03-21 Benjamin Wiegland Personal care formulations
US20020035046A1 (en) * 1999-07-01 2002-03-21 Lukenbach Elvin R. Personal care compositions
US6544255B2 (en) * 1997-04-04 2003-04-08 Keralase Ltd. Method of hair removal by transcutaneous application of laser light
US20040009142A1 (en) * 2000-07-26 2004-01-15 Marie-France Zambaux Synergistically active mixture which inhibits hair growth
US20040067244A1 (en) * 1999-03-22 2004-04-08 Friedman Doron I. Nano oil in glycerin emulsion
US20050008665A1 (en) * 2001-10-13 2005-01-13 Beiersdorf Ag Cosmetic or dermatological active ingredient combination
US20050019279A1 (en) * 2001-11-09 2005-01-27 Beiersdorf Ag Cosmetic or dermatological preparation containing an octadecene dioic acid and a UV filtering substance
US20070009459A1 (en) * 2003-08-26 2007-01-11 Stephanie Magnant Stabilized antiperspirant compositions containing soy products
US20070041931A1 (en) * 2003-10-29 2007-02-22 Muriel Morelli Compositions Comprising Soy Products and Dioic Acids

Family Cites Families (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2924525A (en) 1957-06-03 1960-02-09 Central Soya Co Poultry treatment for skin pigmentation
US3097947A (en) 1961-01-30 1963-07-16 Mend Johnson & Company Nutritional composition and process
US3395214A (en) 1964-01-09 1968-07-30 Scholl Mfg Co Inc Antiperspirant composition providing a readily collapsible sprayable foam
FR2041594A5 (en) 1969-04-30 1971-01-29 Expanscience
US3625976A (en) 1969-12-09 1971-12-07 Int Flavors & Fragrances Inc Coumarin ether sun-screening compounds
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US4056637A (en) 1976-06-08 1977-11-01 Japan Natural Food Co. Ltd. Process for preparing food products containing a lactic acid bacteria-fermented product of a cereal germ
US4279930A (en) 1978-10-10 1981-07-21 The Upjohn Company Process for treating inflammation
US4219569A (en) 1978-10-10 1980-08-26 The Upjohn Company Process for treating inflammation
US4223018A (en) 1979-02-09 1980-09-16 Jimmie Belle Bath composition
DE3040246C2 (en) 1979-10-29 1985-01-10 Osaka Chemical Laboratory Co., Ltd., Osaka Soy Saponins A ↓ 1 ↓ and A? 2? and their use
US4297348A (en) 1980-04-11 1981-10-27 Rush-Hampton Industries, Inc. Composition and method for the treatment of acne
US5439672A (en) 1980-07-01 1995-08-08 L'oreal Cosmetic composition based on an aqueous dispersion of small lipid spheres
US4272544A (en) 1980-08-20 1981-06-09 Eli Lilly And Company Skin cell renewal regime
US4278570A (en) 1980-08-20 1981-07-14 Eli Lilly And Company Cosmetic cleanser formulation
LU83020A1 (en) 1980-12-19 1982-07-07 Oreal OIL COMPOSITION FOR THE TREATMENT OF KERATINIC MATERIALS AND THE SKIN
US4603146A (en) 1984-05-16 1986-07-29 Kligman Albert M Methods for retarding the effects of aging of the skin
US4859458A (en) 1981-09-15 1989-08-22 Morton Thiokol, Inc. Hair conditioning polymers containing alkoxylated nitrogen salts of sulfonic acid
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FR2514643B1 (en) 1981-10-20 1986-07-04 Oreal COPPER LANOLATE AND ANTI-ACNE COSMETIC COMPOSITIONS CONTAINING THE SAME
FR2520253A1 (en) 1982-01-28 1983-07-29 Oreal NOVEL EMULSIFYING SYSTEM BASED ON PROTEIN CONDENSATION, POLYOXYETHYLENE STEROL AND PHOSPHATIDE AND USE THEREOF IN COSMETICS
US4477434A (en) 1982-05-29 1984-10-16 Reiko Kosaka Medicinal compositions, foods and beverages having therapeutic effects on diseases of circulatory system and digestive system
JPS6019885B2 (en) * 1982-06-23 1985-05-18 一丸フアルコス株式会社 Whitening cosmetics containing isoflavone compounds
US4462981A (en) 1982-12-10 1984-07-31 Creative Products Resource, Associates Ltd. Cosmetic applicator useful for skin moisturizing and deodorizing
US4550035A (en) 1982-12-10 1985-10-29 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing and deodorizing
US4604281A (en) 1983-03-21 1986-08-05 Charles Of The Ritz Group Ltd. Cosmetic and skin treatment compositions containing acetylated sterols
JPS59187756A (en) 1983-04-08 1984-10-24 Erika Kk Powdery soybean milk
DE3326455A1 (en) 1983-07-22 1985-01-31 Henkel Kgaa COSMETIC-PHARMACEUTICAL OIL COMPONENTS
JPS6061513A (en) 1983-09-14 1985-04-09 Sansho Seiyaku Kk Cosmetic
IT1180156B (en) 1984-01-09 1987-09-23 Crinos Industria Farmaco GLYCOPROTEIN-BASED COSMETIC COMPOSITION FOR SKIN TREATMENT
US4690821A (en) 1984-02-10 1987-09-01 Creative Products Resource Associates, Ltd. Towel for skin moisturizing and drying
ATE81449T1 (en) 1984-03-05 1992-10-15 Tonfer Inc CLEANING SUPPLIES.
AU580645B2 (en) 1984-12-21 1989-01-19 Kibun Company Limited Process of producing soy bean milk
JPS6236304A (en) 1985-06-05 1987-02-17 Kashiwa Kagaku Kogyo:Kk Cosmetic
US4760096A (en) 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation
US4793991A (en) 1986-01-31 1988-12-27 Slimak Karen M Hypoallergenic cosmetics, lip balms and lip sticks
US4847267A (en) 1986-03-17 1989-07-11 Charles Of The Ritz Group Ltd. Skin treatment composition and method
US4970216A (en) 1986-03-17 1990-11-13 Richardson Vicks, Inc. Skin treatment composition and method
LU86361A1 (en) 1986-03-19 1987-11-11 Oreal AQUEOUS COSMETIC COMPOSITION WITH DIFFERENT FOAM FOR THE TREATMENT OF HAIR AND SKIN
FR2641696B2 (en) 1986-04-11 1991-03-08 Sederma Sa USE OF A MIXTURE CONTAINING LACTOFERRIN IN FREE ANTI-RADICAL COSMETIC PREPARATIONS
FR2596986B1 (en) 1986-04-11 1988-09-23 Sederma Sa USE OF LACTOFERRIN IN COSMETIC, FREE ANTIRADICAL PREPARATIONS
FR2600250B1 (en) 1986-06-23 1989-11-24 Bio Serae PROCESS FOR PACKAGING AN ANTIBACTERIAL COMPOSITION AND PACKAGED ANTIBACTERIAL COMPOSITION
JPS63135310A (en) 1986-11-27 1988-06-07 Lion Corp Cosmetic
LU86715A1 (en) 1986-12-16 1988-07-14 Oreal COSMETIC COMPOSITION CONTAINING HYDROXYLATED CHALCON DERIVATIVES AND ITS USE FOR PROTECTING SKIN AND HAIR AGAINST LIGHT RADIATION, NEW HYDROXYLATED CHALCON DERIVATIVES AND THEIR PREPARATION METHOD
AU618517B2 (en) 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
IT1201149B (en) 1987-01-14 1989-01-27 Indena Spa BIOFLAVONOID COMPLEXES WITH PHOSPHOLIPIDS, THEIR PREPARATION, USE AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS
IT1203515B (en) 1987-02-26 1989-02-15 Indena Spa SAPONINE COMPLEXES WITH PHOSPHOLIPIDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM
US5166139A (en) 1987-02-26 1992-11-24 Indena, S.P.A. Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them
US4960764A (en) 1987-03-06 1990-10-02 Richardson-Vicks Inc. Oil-in-water-in-silicone emulsion compositions
DE3712986A1 (en) 1987-04-16 1988-10-27 Marbert Gmbh MEDICAL PREPARATIONS BASED ON TREASURE EXTRACT, METHOD FOR THE PRODUCTION THEREOF AND USE OF TREATMENT EXTRACT FOR THE PRODUCTION OF COSMETIC PREPARATIONS AND A SPECIAL TREATMENT EXTRACT
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5688763A (en) 1987-06-12 1997-11-18 Hammonds, Jr.; R. Glenn Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
LU86997A1 (en) 1987-09-21 1989-04-06 Oreal PHOTOSTABLE FILTERING COSMETIC COMPOSITION CONTAINING BIXIN ASSOCIATED WITH A LIPOSOLUBLE UV FILTER AND ITS USE FOR THE PROTECTION OF THE HUMAN SKIN AGAINST ULTRAVIOLET RADIATION
JP2618657B2 (en) 1987-10-02 1997-06-11 株式会社資生堂 External preparation for anti-pigmentation
JPH0196106A (en) 1987-10-09 1989-04-14 Shiseido Co Ltd External drug for skin
CH676470A5 (en) 1988-02-03 1991-01-31 Nestle Sa
FR2628317B1 (en) 1988-03-09 1991-11-08 Lvmh Rech COMPOSITION BASED ON HYDRATED LIPID LAMID PHASES OR LIPOSOMES CONTAINING SCUTELLARIA EXTRACT, OR AT LEAST ONE FLAVONOID SUCH AS BAICALINE OR BAICALINE AND COSMETIC OR PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, ANTI-ALLERGIC ANTI-ALLERGIC ACTIVITY THE INCORPORANT
IT1219587B (en) 1988-05-13 1990-05-18 Fidia Farmaceutici SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES
US4851214A (en) 1988-09-07 1989-07-25 Ici Americas Inc. Deodorants containing N-soya-N-ethyl morpholinium ethosulfate
US4960588A (en) 1988-11-16 1990-10-02 Helene Curtis, Inc. Hair treatment compositions to impart durable hair set retention properties
US4943462A (en) 1989-01-17 1990-07-24 Semex Medical, Inc. Nail treatment device
LU87449A1 (en) 1989-02-09 1990-09-19 Oreal PROCESS FOR THE MANUFACTURE OF FOAMS FOR USE IN THE COSMETIC AND PHARMACEUTICAL AREAS AND FOAMS OBTAINED BY THIS PROCESS
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
DE69027475T2 (en) 1989-04-14 1996-12-12 Jessen Wesley Corp Process for coloring contact lenses
MY105521A (en) 1989-04-17 1994-10-31 Healthpoint Ltd Moisturizing vehicle for topical application of vitamin a acid.
US5077038A (en) 1989-07-27 1991-12-31 Vi-Jon Laboratories, Inc. Nail polish remover
JPH04501882A (en) 1989-09-14 1992-04-02 チヤン,シン―シウン Flexible gas permeable contact lenses with improved clinical performance
JP2832848B2 (en) 1989-10-21 1998-12-09 株式会社林原生物化学研究所 Crystal 2-O-α-D-glucopyranosyl-L-ascorbic acid, its production method and use
EP0421021A1 (en) 1989-10-06 1991-04-10 MUCOS EMULSIONSGESELLSCHAFT m.b.H. Use of catabolic enzymes to activate macrophages and/or NK cells, medicinal composition containing these enzymes for the activation of macrophages and/or NK cells
US5554647A (en) 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
US5032400A (en) 1989-11-02 1991-07-16 Erie Laboratories Shark liver oil and garlic oil topical analgesic
US5834312A (en) 1990-01-29 1998-11-10 Hy-Gene, Inc. Process and media for the growth of human epithelia
US5077040A (en) 1990-04-30 1991-12-31 Helene Curtis, Inc. Hair-treating microemulsion composition and method of preparing and using the same
US5332758A (en) 1990-07-13 1994-07-26 Kanebo, Ltd. Collagen metabolism ameliorant and its use
CA2047160C (en) 1990-07-25 2002-06-25 Masahiro Ito Reactive hot-melt elastic sealant composition
US5231090A (en) 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
FR2666474B1 (en) 1990-08-28 1992-11-06 De Stoutz Jean DEVICE FOR HEATING FLUIDS BY JOUL EFFECT.
US5376373A (en) * 1990-09-06 1994-12-27 Trustees Of The University Of Pennsylvania Method of inhibiting radiation induced weight and hair loss
US5217717A (en) 1990-09-06 1993-06-08 Central Soya Company, Inc. Method of making soybean Bowman-Birk inhibitor concentrate and use of same as a human cancer preventative and therapy
US5130142A (en) 1990-10-31 1992-07-14 The Practer & Gamble Company Hair growth regulating composition comprising epithelium cell supernatant-derived growth factor
CA2073353C (en) 1990-11-14 2003-10-28 Alexandre Zysman Glycerol-derived non ionic amphiphilic compounds, a process for their preparation, corresponding intermediary compounds and compositions containing said compounds
KR100191144B1 (en) 1990-11-27 1999-06-15 스티븐 에이 헬렁 Surface-active macromonomers
US5135297A (en) 1990-11-27 1992-08-04 Bausch & Lomb Incorporated Surface coating of polymer objects
US5449794A (en) 1991-02-15 1995-09-12 Jasmine Fockerman Benzopyran phenol derivatives for use as antibacterial agents
GB9104286D0 (en) 1991-02-28 1991-04-17 Phytopharm Ltd Pharmaceutical compositions for the treatment of skin disorders
US5807543A (en) 1993-08-27 1998-09-15 The Procter & Gamble Co. Cosmetic compositions containing hydrophobically modified nonionic polymer and unsaturated quaternary ammonium surfactant
JPH05114905A (en) 1991-04-08 1993-05-07 Digital Equip Corp <Dec> Message processing filtering using single address and protocol table bridge
US5229104A (en) 1991-04-29 1993-07-20 Richardson-Vicks Inc. Artificial tanning compositions containing positively charged paucilamellar vesicles
EP0514576A1 (en) 1991-05-24 1992-11-25 Societe Des Produits Nestle S.A. Oil-soluble antioxidant mixture
JP3320430B2 (en) 1991-07-10 2002-09-03 日本原子力研究所 Method for producing sterile phospholipid, aqueous phospholipid dispersion or aqueous liposome dispersion by radiation sterilization
JP3135940B2 (en) * 1991-07-12 2001-02-19 株式会社コーセー Hair growth inhibitor
FR2679446B1 (en) 1991-07-24 1993-10-29 Oreal METHOD FOR MANUFACTURING A COSMETIC COMPOSITION FOR APPLICATION TO HAIR, COMPOSITION OBTAINED BY THIS PROCESS AND METHOD FOR COSMETIC TREATMENT USING THE SAME.
US5254331A (en) 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
EP0532465B1 (en) 1991-09-13 2002-07-10 Pentapharm A.G. Protein fraction for cosmetic and dermatological care of the skin
US5260065A (en) 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
US5780459A (en) 1991-11-25 1998-07-14 The Procter & Gamble Company Compositions for regulating skin wrinkles and or skin atrophy
FR2685202B1 (en) 1991-12-24 1995-03-24 Sederma Sa NOVEL PHARMACEUTICAL AND COSMETIC TREATMENT METHOD FOR THE REGULATION OF SEBORRHEA, ACNE AND SKIN FLORA.
US5766628A (en) 1992-02-24 1998-06-16 Merz + Co. Gmbh & Co. Bath and shower composition having vesicle-forming properties and method for the production and use thereof
DE4206090C2 (en) 1992-02-27 1998-02-05 Perycut Chemie Ag Insect repellent
US5248495A (en) 1992-04-16 1993-09-28 The Procter & Gamble Company Post foaming shaving gel composition
JPH0649251A (en) 1992-06-09 1994-02-22 Ciba Geigy Ag Method of grafting onto surface of premolded substrate to modify surface property
US5352443A (en) 1992-06-15 1994-10-04 Shiseido Co., Ltd. Permanent waving composition
FR2692783B1 (en) 1992-06-25 1995-05-05 Expanchimie Compositions based on unsaponifiable fractions of wheat germ and sesame oils, and their uses in particular in cosmetology and as a food supplement.
US5641509A (en) 1992-06-26 1997-06-24 Lancaster Group Ag Preparation for topical use
US5643601A (en) 1992-06-26 1997-07-01 Lancaster Group Ag Phospholipid-and fluorocarbon-containing cosmetic
DE4221256C2 (en) 1992-06-26 1997-07-10 Lancaster Group Ag Galenic composition for topical use
US5438044A (en) 1992-06-30 1995-08-01 Rhone-Poulenc Rorer Phospholipid composition
ES2136105T3 (en) 1992-08-04 1999-11-16 Rhone Poulenc Rorer Gmbh PHARMACEUTICAL AND / OR COSMETIC PREPARATION.
JPH06192085A (en) 1992-08-31 1994-07-12 Yuji Inada Therapeutic agent for mite allergy
IL106922A (en) 1992-09-14 1998-08-16 Novartis Ag Composite materials with one or more wettable surfaces and process for their preparation
US5683380A (en) 1995-03-29 1997-11-04 Esc Medical Systems Ltd. Method and apparatus for depilation using pulsed electromagnetic radiation
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
JP3257091B2 (en) 1992-11-06 2002-02-18 不二製油株式会社 Anti-skin cancer agent or food
JP2580942B2 (en) 1992-12-24 1997-02-12 ティアック株式会社 Magnetic tape device and method of moving the magnetic head
JP3432848B2 (en) * 1993-01-25 2003-08-04 富山化学工業株式会社 Hair restorer
US5270042A (en) 1993-02-23 1993-12-14 Juanita Whitham Medicinal salve composition
RU2066992C1 (en) 1993-03-01 1996-09-27 Надежда Михайловна Остроумова Method and remedy for removing hairs
JP3091045B2 (en) 1993-03-04 2000-09-25 丸善製薬株式会社 Skin cosmetics
CA2119064A1 (en) 1993-03-17 1994-09-18 Richard A. Berg Dermal-epidermal in vitro test system
CN1094279A (en) * 1993-04-22 1994-11-02 王能强 Pure natural medicine type physiotherapy health and hair-nursing shampoo
CN1081899A (en) 1993-04-24 1994-02-16 王丽华 Broad-spectrum ointment
TW253849B (en) 1993-08-09 1995-08-11 Ciba Geigy
FR2709756B1 (en) 1993-09-10 1995-10-20 Essilor Int Hydrophilic, transparent material with high oxygen permeability, based on a polymer with interpenetrating networks, its method of preparation and manufacture of soft contact lenses with high oxygen permeability.
FR2710524B1 (en) 1993-09-28 1995-11-17 Oreal Composition of nail polish containing an epoxidized oil as a plasticizer.
US5641863A (en) 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
IL111105A (en) 1993-09-30 2009-05-04 Univ Pennsylvania Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis
US5681571A (en) 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
JPH07121869B2 (en) 1993-10-12 1995-12-25 浩 前田 Inhibitors of inflammatory edema promotion
GB9322007D0 (en) 1993-10-26 1993-12-15 Unilever Plc Cosmetic composition
US5681852A (en) 1993-11-12 1997-10-28 The Procter & Gamble Company Desquamation compositions
EP0655470B1 (en) 1993-11-26 1999-05-12 Novartis AG Cross-linkable copolymers and hydrogels
DE4343431C1 (en) 1993-12-18 1995-05-04 Henkel Kgaa Cosmetic and/or pharmaceutical compositions
JPH07196527A (en) 1993-12-29 1995-08-01 Morinaga Milk Ind Co Ltd Peptide or its derivative and cell growth activator
JPH07196529A (en) 1993-12-29 1995-08-01 Morinaga Milk Ind Co Ltd Wound-curing agent, cosmetic and hair tonic
FR2714602B1 (en) 1993-12-30 1996-02-09 Oreal Anti-acne composition for the simultaneous treatment of the superficial and deep layers of the skin, its use.
FR2714604B1 (en) 1993-12-30 1996-01-26 Oreal Use of a spin acceptor in a cosmetic or dermatological composition.
FR2714597B1 (en) 1993-12-30 1996-02-09 Oreal Moisturizing composition for the simultaneous treatment of the superficial and deep layers of the skin, its use.
FR2714598B1 (en) 1993-12-30 1996-02-09 Oreal Slimming composition with two types of liposomes for topical treatment, its use.
US5468473A (en) 1994-02-09 1995-11-21 Innova Products, Inc. Antiperspirant for hands and feet
IL112649A (en) 1994-02-22 1999-12-22 Curtis Helene Ind Inc Topically effective compositions for application to the skin or hair
US5547661A (en) 1994-02-22 1996-08-20 Helene Curtis, Inc. Antiperspirant deodorant compositions
FR2717075B1 (en) 1994-03-14 1996-04-05 Oreal Aqueous organopolysiloxane makeup gel.
US5455234A (en) 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
FR2719219B1 (en) 1994-05-02 1996-06-21 Rocher Yves Biolog Vegetale Cosmetic or pharmaceutical composition for topical use comprising lipid vesicles.
JP3127713B2 (en) 1994-05-10 2001-01-29 株式会社村田製作所 Optimal condition analysis method for powder molding
JPH07304655A (en) 1994-05-13 1995-11-21 Kikkoman Corp Bathing agent and its production
FR2720937B1 (en) 1994-06-08 1997-03-28 Oreal Cosmetic or dermatological composition in the form of an aqueous and stable dispersion of cubic gel particles based on phytantriol and containing a fatty chain surfactant as a dispersing and stabilizing agent.
JPH0812560A (en) 1994-06-29 1996-01-16 Shiseido Co Ltd Skin external preparation
JPH0812531A (en) * 1994-06-30 1996-01-16 Yakurigaku Chuo Kenkyusho:Kk Trichogen and depilatory compound with lipid extracted from coix seed
DE4424210C2 (en) 1994-07-09 1997-12-04 Beiersdorf Ag Use of compositions containing surfactants and containing oil components, which are otherwise water-free, as cosmetic or dermatological shower oils
US5444092A (en) 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
JPH0859450A (en) 1994-08-18 1996-03-05 Kose Corp External preparation for skin
WO1996007396A2 (en) 1994-09-07 1996-03-14 Johnson & Johnson Consumer Products, Inc. Retinoid compositions
JP3537878B2 (en) * 1994-09-12 2004-06-14 邦郎 辻 Hair growth inhibitor and cosmetics containing it
DE4433071C1 (en) 1994-09-16 1995-12-21 Henkel Kgaa Mild detergent mixtures
DE4432947C2 (en) 1994-09-16 1998-04-09 New Standard Gmbh Agent for the treatment of the skin and its use
US5554608A (en) 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
JPH08143442A (en) 1994-11-16 1996-06-04 Kikkoman Corp Skin external preparation and its production
US5567420A (en) 1994-11-16 1996-10-22 Mceleney; John Lotion which is temporarily colored upon application
JP3647093B2 (en) 1994-11-17 2005-05-11 株式会社メニコン Hydrophilized oxygen permeable contact lens and method for producing the same
EP0796084B1 (en) 1994-12-06 1999-05-06 The Procter & Gamble Company Shelf stable skin cleansing liquid with gel forming polymer, lipid and crystalline ethylene glycol fatty acid ester
BR9607516A (en) 1995-02-07 1997-12-30 Fidia Advanced Biopolymers Srl Process for coating objects with hyaluronic acid derived from them and semi-synthetic polymers
FR2730928B1 (en) 1995-02-23 1997-04-04 Oreal COMPOSITION BASED ON LIPIDIC VESICLES WITH ACIDIC PH AND USE THEREOF IN TOPICAL APPLICATION
CN1078459C (en) 1995-03-23 2002-01-30 朗卡斯特集团有限公司 Cosmetic agent with condensed decomposition products of plant and animal origin
US5985809A (en) 1995-05-27 1999-11-16 The Procter & Gamble Company Aqueous personal cleansing compositions comprising specific nonocclusive liquid polyol fatty acid polyester
US5942479A (en) 1995-05-27 1999-08-24 The Proctor & Gamble Company Aqueous personal cleansing composition with a dispersed oil phase comprising two specifically defined oil components
GB9510833D0 (en) 1995-05-27 1995-07-19 Procter & Gamble Cleansing compositions
JP3911642B2 (en) 1995-06-06 2007-05-09 株式会社加美乃素本舗 Topical skin preparation
CA2223747A1 (en) 1995-06-07 1996-12-19 Taisho Pharmaceutical Co., Ltd. Antifungal compositions
CA2223402C (en) 1995-06-07 2012-07-31 University Of Pennsylvania Methods of inhibiting phagocytosis
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US5639785A (en) 1995-06-07 1997-06-17 Global Pharma, Ltd. Methods for the treatment of baldness and gray hair using isoflavonoid derivatives
JPH0840824A (en) 1995-06-21 1996-02-13 Nonogawa Shoji Kk Cosmetic
JP3027008B2 (en) 1995-06-21 2000-03-27 ロレアル Cosmetic composition containing polymer particle dispersion
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
CN1146876A (en) 1995-06-28 1997-04-09 李缯宏 Beauty bean milk
JP3410870B2 (en) 1995-07-13 2003-05-26 株式会社資生堂 External preparation for skin
JPH0925213A (en) 1995-07-13 1997-01-28 Shiseido Co Ltd Skin preparation for external use
JPH0925212A (en) 1995-07-13 1997-01-28 Shiseido Co Ltd Skin preparation for external use
US5571503A (en) 1995-08-01 1996-11-05 Mausner; Jack Anti-pollution cosmetic composition
US5874127A (en) 1995-08-16 1999-02-23 Ciba Vision Corporation Method and apparatus for gaseous treatment
JP3302535B2 (en) * 1995-08-17 2002-07-15 キッコーマン株式会社 Epithelial cell growth promoter
JPH0977638A (en) 1995-09-19 1997-03-25 Art Beauty Clinic Kk Foundation for cosmetic
US6063398A (en) 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5683683A (en) 1995-09-21 1997-11-04 Helene Curtis, Inc. Body wash composition to impart conditioning properties to skin
US5635165A (en) 1995-09-27 1997-06-03 Helene Curtis, Inc. Antiperspirant deodorant compositions
NZ299379A (en) 1995-10-27 1997-04-24 Unilever Plc Topical flavanone-containing composition
US6509098B1 (en) 1995-11-17 2003-01-21 Massachusetts Institute Of Technology Poly(ethylene oxide) coated surfaces
JP3945544B2 (en) 1995-12-27 2007-07-18 ピジョン株式会社 Method for producing soybean extract
US5961980A (en) 1996-01-18 1999-10-05 The Trustees Of The University Of Pennsylvania Bowman-birk inhibitor compositions and methods for the treatment of genitourinary diseases
US5643587A (en) 1996-02-15 1997-07-01 Avon Products, Inc. Composition and method for under-eye skin lightening
TW340287B (en) 1996-02-23 1998-09-11 Tamura Electric Works Ltd Housing
AU1793397A (en) 1996-03-29 1997-10-22 S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite
FR2747568B1 (en) 1996-04-17 1999-09-17 Oreal USE OF AT LEAST ONE LIPOXYGENASE INHIBITOR AND AT LEAST ONE CYCLO-OXYGENASE INHIBITOR FOR MODIFYING HAIR AND / OR HAIR GROWTH
WO1997039734A1 (en) 1996-04-23 1997-10-30 The Procter & Gamble Company Methods of regulating skin condition with centella asiatica extract
US5834513A (en) 1996-04-25 1998-11-10 Avon Products, Inc. Oxa diacids and related compounds for treating skin conditions
CN1166960A (en) 1996-06-04 1997-12-10 金建文 Composite beauty masque powder containing spirulina
US5824702A (en) 1996-06-07 1998-10-20 Mount Sinai School Of Medicine Of The City University Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
US5821361A (en) 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
BR9602991A (en) 1996-07-05 1998-04-28 Cosmeticos Natural Ind Com Skin moisturizing and protective cosmetic compositions against ultraviolet and infrared radiation
BR9603084A (en) 1996-07-12 1998-05-05 Cosmeticos Natural Ind Com Dry emulsion composition for skin
US5888522A (en) 1996-08-23 1999-03-30 Skin Biology, Inc. Tissue protective and regenerative compositions
JPH10120560A (en) 1996-08-26 1998-05-12 Sankyo Co Ltd Loxoprofen-containing preparation for external use
DE19634206C2 (en) 1996-08-26 2000-01-20 Ludwig Reinke Skin care products, in particular for aging skin
US5804234A (en) 1996-09-13 1998-09-08 Suh; John D. Plant protein for nutritional products and method of making same
DE19638534A1 (en) 1996-09-20 1998-03-26 Beiersdorf Ag Use of tocopheryl ferulate as skin bleaching agent
US5665367A (en) 1996-09-27 1997-09-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin care compositions containing naringenin and/or quercetin and a retinoid
FR2754713B1 (en) 1996-10-22 1999-01-08 Roc Sa USE OF COMPLEXES FOR THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF SENSITIVE SKIN, PREPARATION METHOD AND HYPOALLERGENIC COMPOSITIONS
JPH10139639A (en) 1996-11-07 1998-05-26 Kao Corp Hair growth-inhibiting agent
JPH10139654A (en) 1996-11-08 1998-05-26 Lion Corp Composition for external skin use
FR2757767B1 (en) 1996-12-27 1999-02-05 Oreal TOPICAL COMPOSITION CONTAINING AT LEAST ONE PLANT-BASED PROTEIN AND / OR ANIMAL-BASED PROTEIN AND A POLY (2-ACRYLAMIDO 2-METHYLPROPANE SULFONIC ACID) CROSSLINKED
US6205815B1 (en) 1997-04-11 2001-03-27 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Plant for separation of a gas mixture by distillation
DE19818849A1 (en) 1997-04-28 1998-10-29 Med Beauty Ag Formulation to promote deep skin penetration
US5962015A (en) 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Stabilized liposomes
US6183762B1 (en) 1997-05-27 2001-02-06 Sembiosys Genetics Inc. Oil body based personal care products
US6060070A (en) 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
FR2765106B1 (en) 1997-06-27 2000-12-15 Dior Christian Parfums USE OF CROSSLINKED TANNINS IN THE PRESENCE OF NON-CROSSLINKED PROTEINS WITH TANNINS AS COSMETIC AGENTS TO IMPROVE SKIN SMOOTHING AND / OR TO OBTAIN AN ASTRINGENT EFFECT
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US6273885B1 (en) 1997-08-16 2001-08-14 Cooltouch Corporation Handheld photoepilation device and method
DE19735587B4 (en) 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum A peptide having a radioprotective effect, a cosmetic or pharmaceutical composition containing the same, a nucleic acid encoding the same, a preparation process for this peptide and the use as a radioprotective agent
CN1215587A (en) * 1997-08-21 1999-05-05 株式会社资生堂 Cosmetic composition
EP1023617A1 (en) 1997-09-23 2000-08-02 Novartis AG Method for hydrogel surface treatment and article formed therefrom
US5972355A (en) 1997-09-30 1999-10-26 E-L Management Corp. Stable compositions containing biologically active components
US5928658A (en) 1997-12-05 1999-07-27 U.S. Cosmetics Oil-free wax-free solid cosmetic composition
CA2314899A1 (en) 1997-12-16 1999-06-24 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for regulating phagocytosis and icam-1 expression
US5958946A (en) * 1998-01-20 1999-09-28 Styczynski; Peter Modulation of hair growth
DE19804376B4 (en) 1998-02-04 2004-09-16 Johnson & Johnson Gmbh Lipid mixtures and their use
US5928889A (en) 1998-02-13 1999-07-27 S.C. Johnson & Son, Inc. Protocol for simulated natural biofilm formation
JPH11243895A (en) * 1998-03-03 1999-09-14 Kikkoman Corp New soybean milk
US5965153A (en) 1998-03-24 1999-10-12 Stabar Enterprises, Inc. Dietary supplement for preventing or reducing shedding by animals
US6323219B1 (en) * 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
EP1080139A1 (en) 1998-05-05 2001-03-07 Bausch & Lomb Incorporated Plasma surface treatment of silicone hydrogel contact lenses
JP3784962B2 (en) 1998-05-14 2006-06-14 一丸ファルコス株式会社 Hair growth inhibitor
US5985842A (en) * 1998-05-14 1999-11-16 Miljkovic; Dusan Boron compounds/complexes to control hair growth, and methods of use
JPH11346695A (en) 1998-06-03 1999-12-21 Natl Food Res Inst Production of soybean milk
US6087415A (en) 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US6365802B2 (en) * 1998-08-14 2002-04-02 Calgene Llc Methods for increasing stearate content in soybean oil
DE69932621D1 (en) 1998-10-09 2006-09-14 Yakult Honsha Kk SKIN CARE PREPARATIONS FOR EXTERNAL APPLICATION
US6096327A (en) 1998-11-05 2000-08-01 Protease Sciences Inc. Cosmetic compositions containing human type serine protease inhibitors for revitalizing the skin
US20020197244A1 (en) 1998-12-07 2002-12-26 Miri Seiberg Compositions and methods for regulating phagocytosis and ICAM-1 expression
JP2000191459A (en) * 1998-12-25 2000-07-11 Lion Corp Hair growth suppressor and cosmetic
EP1148891B1 (en) 1999-01-19 2004-03-17 PHARMACIA &amp; UPJOHN COMPANY Method of packaging an oxidation sensitive medicinal substance
AU3390400A (en) 1999-03-05 2000-09-21 Johns Hopkins University, The Regulating skin appearance and composition with a fluorinated vitamin d3 analog compound
US6383176B1 (en) 1999-03-15 2002-05-07 Altus Medical, Inc. Hair removal device and method
US6413546B1 (en) 1999-03-18 2002-07-02 Indena, S.P.A. Tablets incorporating isoflavone plant extracts and methods of manufacturing them
CN1347309A (en) 1999-04-19 2002-05-01 宝洁公司 Skin care compositions contg. combination of skin care actives
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
WO2000062741A2 (en) 1999-04-19 2000-10-26 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
US6444647B1 (en) 1999-04-19 2002-09-03 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
JP2000302678A (en) 1999-04-21 2000-10-31 Kuressendo Corporation:Kk Hair activity by isoflavone derived from soybean
US6261603B1 (en) 1999-05-11 2001-07-17 Mcelwain Elizena A. Skin cream
US6447809B1 (en) 1999-05-11 2002-09-10 Metagenics, Inc. Composition for promoting healthy bone structure
JP3661981B2 (en) 1999-06-09 2005-06-22 株式会社ノエビア Antiperspirant
DE19927229B4 (en) 1999-06-10 2004-09-09 Coty B.V. Cosmetic enzyme and its use
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US6461348B1 (en) 1999-08-27 2002-10-08 Howard S. Bertan Photo-thermal epilation apparatus with advanced energy storage arrangement
BR0007404A (en) 1999-11-05 2002-04-09 Johnson & Johnson Consumer Soy compositions for depigmentation and skin care
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
MXPA02004933A (en) 1999-11-16 2004-08-12 Unilever Nv Cosmetic compositions containing chick pea extract and retinoids.
FR2803747B1 (en) 2000-01-18 2003-12-26 Pharmascience Lab USE OF ISOFLAVONES AND / OR EXTRACTS OF AFRICAN PLUM IN PHARMACY, COSMETICS AND AS A FOOD ADDITIVE.
JP3610278B2 (en) 2000-03-28 2005-01-12 有限会社テイ・ケイ・シイ▲高▼橋コンピュータ会計 Processed rice bran
US6433025B1 (en) 2000-04-13 2002-08-13 Cyanotech Corporation Method for retarding and preventing sunburn by UV light
US6558656B2 (en) 2000-04-20 2003-05-06 Morris Mann Oral and topical compositions and methods related thereto in the treatment of acne
FR2811226B1 (en) 2000-06-05 2003-06-20 Clarins Laboratoires S A S MOISTURIZING COSMETIC COMPOSITION COMPRISING A PLANT TRYPSIN INHIBITOR
KR20020025804A (en) 2000-09-29 2002-04-04 미쉘 지. 멘지니 Composition to enhance permeation of topical skin agents
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US6482446B2 (en) 2000-12-01 2002-11-19 Neutrogena Corporation Astringent composition and method of use
JP4169514B2 (en) 2001-01-31 2008-10-22 松下電器産業株式会社 Method and apparatus for manufacturing spiral electrode group
EP1370294A2 (en) 2001-02-27 2003-12-17 The Regents Of The University Of Michigan Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
US20020160061A1 (en) 2001-02-28 2002-10-31 Claude Saliou Use of legume products for the treatment of external aggressions
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
ATE455579T1 (en) 2001-02-28 2010-02-15 Johnson & Johnson Consumer COMPOSITIONS CONTAINING SOY PRODUCTS
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
MXPA03008391A (en) 2001-03-16 2004-11-12 Johnson & Johnson Composition containing feverfew extract and use thereof.
US20030224075A1 (en) 2002-02-21 2003-12-04 Jue-Chen Liu Soy composition for balancing combination skin
JP2004000019A (en) 2002-03-27 2004-01-08 Ikeda Shokken Kk Denaturation inhibitor and liquid composition
US20040063593A1 (en) 2002-09-30 2004-04-01 Wu Jeffrey M. Compositions containing a cosmetically active organic acid and a legume product
EP1543823A1 (en) 2003-12-19 2005-06-22 Johnson & Johnson Consumer France SAS Gingko containing formulations for the improvement of skin radiance
AU2005203059B2 (en) 2004-07-16 2011-11-24 Johnson & Johnson Consumer Companies, Inc. Use of legume products for the treatment and prevention of radiotherapy-induced skin damage

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2876164A (en) * 1957-08-01 1959-03-03 Dome Chemicals Inc Dermatological preparation containing defatted soy bean flour
US4007266A (en) * 1968-05-03 1977-02-08 Choay S.A. Pharmaceutical composition containing vitamin B12, process of making the same and method of treatment
US4331692A (en) * 1971-07-23 1982-05-25 Ulla Drevici Cocoa fruits and products
US4254105A (en) * 1975-10-11 1981-03-03 The Lion Dentifrice Co., Ltd. Multiple emulsion having a form of water/oil/water phase and process for preparation thereof, and multiple emulsion type cosmetics
US4151304A (en) * 1976-11-05 1979-04-24 Lever Brothers Company Method and composition for moisturizing the skin
US4370315A (en) * 1977-02-22 1983-01-25 Sederma Post-depilatory composition reducing progressively the growth of body hair
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
US4434095A (en) * 1979-02-04 1984-02-28 Institute Organicheskogo Sinteza Cyclic analogue of naturally-occurring phagocytosis-stimulant peptide - threonyl-cyclo-[-N.sup.ε -lysyl-prolyl-arginyl]
US4427670A (en) * 1980-03-27 1984-01-24 Mitsubishi Chemical Industries Limited Skin preparation
US4515778A (en) * 1981-03-12 1985-05-07 Wolfgang Kastell Preparation for conditioning and grooming the hair
US4437895A (en) * 1981-07-23 1984-03-20 Societe Anonyme Dite: L'oreal Mixture of vegetable oils based on jojoba oil and cosmetic compositions comprising the mixture
US4439418A (en) * 1981-07-29 1984-03-27 Henkel Kgaa Topical preparations for the treatment of seborrhea and process for inhibiting sebum production
US4368187A (en) * 1981-08-03 1983-01-11 Eli Lilly And Company Sensitive-skin care regime
US4382960A (en) * 1981-08-03 1983-05-10 Eli Lilly And Company Cosmetic cleanser formulation
US4578267A (en) * 1981-09-15 1986-03-25 Morton Thiokol, Inc. Skin conditioning polymer containing alkoxylated nitrogen salts of sulfonic acid
US4512973A (en) * 1983-10-12 1985-04-23 Genentech, Inc. Method for overcoming trypsin inhibition
US5192332A (en) * 1983-10-14 1993-03-09 L'oreal Cosmetic temporary coloring compositions containing protein derivatives
US4584190A (en) * 1983-11-17 1986-04-22 Kao Corporation Novel chalcone derivatives and ultraviolet absorbers comprising the same
US4727088A (en) * 1984-02-06 1988-02-23 Neutrogena Corporation Retinoid composition having enhanced bioavailability and percutaneous absorption
US4834076A (en) * 1985-04-17 1989-05-30 Millet Jean M Device for treating the external human epithelium, process for its manufacture and process for using such a device
US4824662A (en) * 1987-06-15 1989-04-25 Vi-Jon Laboratories, Inc. Nail polish remover
US4895839A (en) * 1987-07-10 1990-01-23 INDENZA S.p.A. Pharmaceutical and cosmetic compositions containing complexes of flavanolignans with phospholipids
US5104655A (en) * 1987-07-27 1992-04-14 Indena S.P.A. Polyunsaturated acids having vasokinetic action and pharmaceutical and cosmetic formulations containing them
US5002761A (en) * 1988-05-02 1991-03-26 Henkel Kommanditgesellschaft Auf Aktien Hair treatment compositions containing natural ingredients
US4906457A (en) * 1988-09-06 1990-03-06 Washington State University Research Foundation, Inc. Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer
US5116605A (en) * 1989-03-09 1992-05-26 Alt John P Composition and skin treatment method therewith for mitigating acne and male-pattern baldness
US5194252A (en) * 1989-07-27 1993-03-16 Vijon Laboratories, Inc. Moisture retaining aftershave
US5622690A (en) * 1990-04-05 1997-04-22 Nurture, Inc. Seed-derived proteinaceous compositions for reduction of sunburn cell formation
US5179091A (en) * 1990-06-22 1993-01-12 Adir Et Compagnie Chalcones
US5407675A (en) * 1990-08-10 1995-04-18 Etemad-Moghadam; Parviz Method and composition for use on the scalp and eyebrow region of a subject
US5306444A (en) * 1990-08-24 1994-04-26 Shiseido Company Ltd. Washing composition capable of preventing and ameliorating skin irritation
US5110603A (en) * 1991-01-31 1992-05-05 Kao Corporation Bathing preparation for colloidal material
US5188823A (en) * 1991-02-07 1993-02-23 Stepan Company Antiperspirant formulations
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US5310734A (en) * 1991-07-05 1994-05-10 Rhone-Poulenc Rorer Phospholipid composition
US5603949A (en) * 1991-08-01 1997-02-18 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives, for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
US5871480A (en) * 1991-10-29 1999-02-16 Thermolase Corporation Hair removal using photosensitizer and laser
US5595984A (en) * 1991-11-25 1997-01-21 Richardson-Vicks Inc. Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
US5869470A (en) * 1991-11-25 1999-02-09 The Procter & Gamble Company Compositions for regulating skin wrinkles and/or skin atrophy
US5616572A (en) * 1991-11-25 1997-04-01 Richardson-Vicks Inc. Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
US5605894A (en) * 1991-11-25 1997-02-25 Richardson-Vicks Inc. Compositions for regulating skin wrinkles and/or skin atrophy
US5597814A (en) * 1991-11-25 1997-01-28 Richardson-Vicks Inc. Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
US5626868A (en) * 1992-02-18 1997-05-06 L'oreal Cosmetic and/or pharmaceutical composition containing a dispersion of lipid vesicles, process for the preparation of the said dispersion and dispersion of lipid vesicles
US5393519A (en) * 1992-03-27 1995-02-28 Helene Curtis, Inc. Shampoo compositions
US5397497A (en) * 1992-08-07 1995-03-14 Solvay Fluor Und Derivate Gmbh Bath additive composition containing polyglycerol fatty acid ester mixture
US5411742A (en) * 1992-08-24 1995-05-02 L'oreal Compositions for the treatment of acne containing a derivative of salicylic acid and derivatives of salicylic acid
US6048520A (en) * 1992-09-24 2000-04-11 Helene Curtis, Inc. Clear leave-on hair treatment composition and method
US5720772A (en) * 1992-10-20 1998-02-24 Esc Medical Systems Ltd. Method and apparatus for therapeutic electromagnetic treatment
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
US6173762B1 (en) * 1993-07-07 2001-01-16 Kabushiki Kaisha Kobe Seiko Sho Heat exchanger tube for falling film evaporator
US5614180A (en) * 1993-08-30 1997-03-25 Helene Curtis, Inc. Shampoo-conditioner composition
US5741496A (en) * 1993-09-21 1998-04-21 Laboratoires De Biologie Vegetale Yves Rocher Process for the treatment of skins having dry areas and greasy areas
US5510391A (en) * 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
US5712356A (en) * 1993-11-26 1998-01-27 Ciba Vision Corporation Cross-linkable copolymers and hydrogels
US5607666A (en) * 1993-12-22 1997-03-04 L'oreal Cosmetic or dermatological powder, its preparation process and its uses
US5620692A (en) * 1993-12-23 1997-04-15 Nurture, Inc. Oat oil compositions with useful cosmetic and dermatological properties
US5607692A (en) * 1993-12-30 1997-03-04 L'oreal Depigmenting composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
US5629015A (en) * 1993-12-30 1997-05-13 L'oreal Composition for combating ageing acting simultaneously on the surface layers and deep layers of the skin and use thereof
US5601833A (en) * 1993-12-30 1997-02-11 L'oreal Protective, nutritive and/or firming composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
US5614215A (en) * 1993-12-30 1997-03-25 L'oreal Cosmetic composition for the simultaneous treatment of the surface and deep layers of the skin, its use
US5503832A (en) * 1994-02-15 1996-04-02 De Stoutz; Jean-Christian Method for extracting the soluble material from oil-bearing beans or seeds
US6045779A (en) * 1994-02-18 2000-04-04 Henkel Kommanditgesellschaft Auf Aktien Skin and hair aerosol foam preparations containing an alkyl polyglycoside and vegetable oil
US5505946A (en) * 1994-04-01 1996-04-09 Trustees Of Univ Of Pa Bowman-birk inhibitor concentrate compositions and methods for the treatment of pre-malignant tissue
US6013255A (en) * 1994-04-18 2000-01-11 Gist-Brocades B.V. Stable water-in-oil emulsions
US5885617A (en) * 1994-07-12 1999-03-23 Bpsi Holdings, Inc. Moisture barrier film coating composition, method, and coated form
US6033680A (en) * 1994-12-06 2000-03-07 The Procter & Gamble Company Shelf stable skin cleansing liquid with gel forming polymer and lipid
US6180662B1 (en) * 1994-12-13 2001-01-30 Beiersdorf Ag Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
US5723148A (en) * 1995-01-05 1998-03-03 Novartis Corp. Topical pharmaceutical compositions
US5618522A (en) * 1995-01-20 1997-04-08 The Procter & Gamble Company Emulsion compositions
US5885948A (en) * 1995-02-15 1999-03-23 The Procter & Gamble Company Crystalline hydroxy waxes as oil in water stabilizers for skin cleansing liquid composition
US5869031A (en) * 1995-03-23 1999-02-09 Pierre Fabre Dermo-Cosmetique Depigmenting dermatological and/or cosmetic composition
US6013250A (en) * 1995-06-28 2000-01-11 L'oreal S. A. Composition for treating hair against chemical and photo damage
US5885593A (en) * 1995-09-28 1999-03-23 The Andrew Jergens Company Skin care composition including cyclodextrin materials and method for treating skin therewith
US6019962A (en) * 1995-11-07 2000-02-01 The Procter & Gamble Co. Compositions and methods for improving cosmetic products
US5880314A (en) * 1995-11-24 1999-03-09 Mitsui Chemicals, Inc. Hydrochalcone derivatives, cosmetic compositions containing said derivatives and methods of producing the same
US5871823A (en) * 1996-06-19 1999-02-16 Huels Aktiengesellschaft Hydrophilic coating of surfaces of polymeric substrates
US5871743A (en) * 1996-10-31 1999-02-16 Chajuss; Daniel Topical application of soy molasses
US6045548A (en) * 1996-11-07 2000-04-04 Cynosure, Inc. Alexandrite laser system for hair removal and method therefor
US6018001A (en) * 1997-01-23 2000-01-25 Menicon Co., Ltd. Process for producing contact lens with hydrophilic surface and contact lens obtained thereby
US5863546A (en) * 1997-03-02 1999-01-26 Swinehart; James M Cosmetic composition
US5885600A (en) * 1997-04-01 1999-03-23 Burlington Bio-Medical & Scientific Corp. Natural insect repellent formula and method of making same
US6544255B2 (en) * 1997-04-04 2003-04-08 Keralase Ltd. Method of hair removal by transcutaneous application of laser light
US5885596A (en) * 1997-07-23 1999-03-23 Bristol-Myers Squibb Company Methods and compositions for fine lines and/or wrinkles
US6017893A (en) * 1997-08-29 2000-01-25 Natures Sunshine Products, Inc. Use of isoflavones to prevent hair loss and preserve the integrity of existing hair
US6017549A (en) * 1997-09-30 2000-01-25 E-L Management Corp. Non-irritating cosmetic and pharmaceutical compositions
US6054137A (en) * 1997-12-19 2000-04-25 Societe L'oreal S.A. Promoting epidermal renewal with phloroglucinol
US6030931A (en) * 1998-02-03 2000-02-29 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Foaming cleansing skin product
US6183761B1 (en) * 1998-03-16 2001-02-06 The Procter & Gamble Company Compositions for regulating skin appearance
US6051602A (en) * 1998-03-16 2000-04-18 The Procter & Gamble Company Methods for regulating skin appearance
US6217572B1 (en) * 1998-05-22 2001-04-17 Edward L. Tobinick Apparatus and method employing lasers for removal of hair
US20040067244A1 (en) * 1999-03-22 2004-04-08 Friedman Doron I. Nano oil in glycerin emulsion
US20020034489A1 (en) * 1999-06-10 2002-03-21 Benjamin Wiegland Personal care formulations
US20020035046A1 (en) * 1999-07-01 2002-03-21 Lukenbach Elvin R. Personal care compositions
US6358242B1 (en) * 1999-11-12 2002-03-19 Ceramoptec Industries, Inc. Post laser treatment for permanent hair removal
US20040009142A1 (en) * 2000-07-26 2004-01-15 Marie-France Zambaux Synergistically active mixture which inhibits hair growth
US20050008665A1 (en) * 2001-10-13 2005-01-13 Beiersdorf Ag Cosmetic or dermatological active ingredient combination
US20050019279A1 (en) * 2001-11-09 2005-01-27 Beiersdorf Ag Cosmetic or dermatological preparation containing an octadecene dioic acid and a UV filtering substance
US20070009459A1 (en) * 2003-08-26 2007-01-11 Stephanie Magnant Stabilized antiperspirant compositions containing soy products
US20070041931A1 (en) * 2003-10-29 2007-02-22 Muriel Morelli Compositions Comprising Soy Products and Dioic Acids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products
US20100092497A1 (en) * 2006-12-22 2010-04-15 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer

Also Published As

Publication number Publication date
EP1074240A3 (en) 2003-01-29
ES2347316T3 (en) 2010-10-28
US7985404B1 (en) 2011-07-26
CN1316272A (en) 2001-10-10
ATE474551T1 (en) 2010-08-15
CA2314562A1 (en) 2001-01-27
CN100337685C (en) 2007-09-19
JP2001072555A (en) 2001-03-21
DE60044697D1 (en) 2010-09-02
HK1032540A1 (en) 2001-07-27
CA2314562C (en) 2011-08-23
KR20010015444A (en) 2001-02-26
US20030064048A1 (en) 2003-04-03
EP1074240A2 (en) 2001-02-07
EP1074240B1 (en) 2010-07-21

Similar Documents

Publication Publication Date Title
US7985404B1 (en) Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
KR100769260B1 (en) Compositions for hair improvement containing rare earth elements
Seiberg et al. Soymilk reduces hair growth and hair follicle dimensions
JP3563449B2 (en) Hair restoration cosmetics
EP1222913B1 (en) Depilating method
CA2563193A1 (en) Use of heat shock protein inhibitors for the reduction of hair growth
AU2008212016B2 (en) Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US20080193403A1 (en) Inducing And Maintaining Hair Color
US20230363999A1 (en) Composition for treating hair loss or promoting hair growth comprising growth factor
JP2000109417A (en) Cosmetic for improving somber color
JP3045613B2 (en) Hair restoration cosmetics
JP2002080327A (en) Hair grower
JPH0820522A (en) Keratinizing anzyme activity promoter and cosmetic containing the same
JP2001139436A (en) Hair tonic and grower
MXPA00007390A (en) Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
JP2002308753A (en) Elastase activity inhibitor, estrogenic activator and anti- aging agent for skin containing the same inhibitor or the same activator
JP2000026269A (en) Cosmetic
JPH0820521A (en) Keratinizing enzyme activity promoter and cosmetic containing the same
JP2002255734A (en) Elastase activity inhibitor and anti-aging agent comprising the same
JPH09227397A (en) Preparation for external use for skin
JPS6016911A (en) Hair tonic
JPH11124317A (en) Composition for head
JPS6168408A (en) Hair tonic
JP4564694B2 (en) Hair growth inhibitor
JP2000169346A (en) Hair tonic

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION